Harnessing nanomedicine for enhanced immunotherapy for breast cancer brain metastases

Christine P. Carney1,2 • Nikhil Pandey1,2 • Anshika Kapur1,2 • Graeme F. Woodworth1,2 • Jeffrey A. Winkles1,2,3,4,7 • Anthony J. Kim1,2,5,6,8

Abstract

Brain metastases (BMs) are the most common type of brain tumor, and the incidence among breast cancer (BC) patients has been steadily increasing over the past two decades. Indeed, ~30% of all patients with metastatic BC will develop BMs, and due to few effective treatments, many will succumb to the disease within a year. Historically, patients with BMs have been largely excluded from clinical trials investigating systemic therapies including immunotherapies (ITs) due to limited brain penetration of systemically administered drugs combined with previous assumptions that BMs are poorly immunogenic. It is now understood that the central nervous system (CNS) is an immunologically distinct site and there is increasing evidence that enhancing immune responses to BCBMs will improve patient outcomes and the efficacy of current treatment regimens. Progress in IT for BCBMs, however, has been slow due to several intrinsic limitations to drug delivery within the brain, substantial safety concerns, and few known targets for BCBM IT. Emerging studies demonstrate that nanomedicine may be a powerful approach to overcome such limitations, and has the potential to greatly improve IT strategies for BMs specifically. This review summarizes the evidence for IT as an effective strategy for BCBM treatment and focuses on the nanotherapeutic strategies currently being explored for BCBMs including targeting the blood–brain/tumor barrier (BBB/BTB), tumor cells, and tumor-supporting immune cells for concentrated drug release within BCBMs, as well as use of nanoparticles (NPs) for delivering immunomodulatory agents, for inducing immunogenic cell death, or for potentiating anti-tumor T cell responses.

Keywords  Breast cancer brain metastases • Nanoparticles • Nanotechnology • Immunotherapy • Nanoimmunotherapies • Immune checkpoint inhibitors • Blood–brain barrier
Introduction

Brain metastases (BMs) are the most common type of intrinsic brain tumor and are associated with an overall poor prognosis, evidenced by median survival <2 months from diagnosis in untreated patients [1]. Treatment with surgery, chemotherapy, and/or radiotherapy (RT) only extends survival by 4–6 months in many tumor types [2], underscoring the need for new therapeutic strategies. BMs most commonly arise from melanoma, lung, and breast cancers (BCs) [3], the latter of which is the focus of this review. Approximately 30% of all patients with metastatic BC will develop BMs (BCBMs) [4, 5]; however, incidence is more common in patients with triple-negative BC (TNBC) and Her2+ BC subtypes. A recent retrospective study estimated that up to 46% of patients with TNBC and 55% of those with Her2+ BC will develop BCBMs; patients with the latter have better prognosis due to the availability of Her2-targeted therapies [6]. Aside from these targeted therapies, which have restricted delivery across the blood–brain/tumor barrier (BBB/BTB), BCBM treatment is largely palliative and typically involves surgery, whole-brain RT (WBRT), stereotactic radiosurgery (SRS), or combinations thereof [7]. Systemic chemotherapies are rarely used due to poor brain penetration and intolerable side effects from high systemic toxicity [8]. Thus, there is a clear and immediate need to expand and improve treatment modalities for BCBM patients.

Patients typically present with BCBMs 2–3 years after diagnosis of the primary breast tumor, which commonly occurs concurrently or after metastatic spread to the lungs, bones, or liver, which represent other frequent sites of BC metastasis [4]. Metastatic spread generally occurs through hematogenous mechanisms, requiring the BC cells to first traverse the BBB. The BBB, which tightly regulates the transport of molecules from the blood, functions within a larger neuro-vascular unit (NVU) consisting of endothelial cells, pericytes, astrocytes, microglia, and neurons that operate in coupled fashion to monitor and maintain cerebrovascular homeostasis [9]. Upon traversing the NVU, BC cells adopt unique signaling pathways and phenotypes in order to survive in this unique CNS microenvironment [10]. Though initially thought to be minimally infiltrated with immune cells [11], it is now understood that establishment of these brain micrometastases requires reactive, inflammatory components including early infiltration and reprogramming of various immune cells and astrocytes within the brain as a “pre-metastatic niche” (PMN) [12]. The apparent reciprocal communication between metastatic and microenvironmental cells therefore represents an intriguing target for BM treatment. Such approaches, however, have been limited to date by the traditional notion that BCs are immunologically cold or minimally immunogenic [13]. Likewise, the CNS has traditionally been considered an immunologically privileged site, devoid of most peripheral immune cells [11]. Combined with limited penetration of conventional drugs into the brain, patients with BMs are excluded from many clinical trials involving systemic or immunotherapies (ITs), limiting current data related to IT for BCBM treatment. Today, the CNS is regarded as an immunologically distinct site under tight regulatory control [14, 15], and there is increasing evidence suggesting that enhancing immune responses against BC cells will greatly improve therapeutic responses and patient survival. Despite the potential of IT, this therapeutic approach faces several specific hurdles for BCBM treatment including significant drug delivery challenges, relatively few targets in BCBM tumors and safety concerns that will continue to hinder translational progress. Nanomedicine, specifically, has the propensity to overcome these barriers and represents a promising strategy for enhancing ITs for BCBMs. Use of nanoparticles (NPs) for intracerebral drug delivery is particularly advantageous due to the ability to engineer and fine-tune NPs for specific biomedical applications. As drug delivery agents, NPs can be decorated with surface ligands to enhance NP targeting to the brain and/or tumor tissues. Further, NPs can encapsulate various therapeutic agents, limiting side effects while enhancing drug stability, and be designed for specific or controlled drug release at the tumor site. Thus, nanotechnology is a potentially valuable tool to improve the delivery, safety, and efficacy of ITs for BCBMs.

In this manuscript, we review emerging studies that provide evidence for IT as an effective strategy for BCBM treatment, assess the substantial physiological barriers limiting clinical translation, and highlight the potential of nanomedicine for improving IT effectiveness. We focus on the capability of nanotechnology to improve IT drug delivery and the therapeutic strategies currently under investigation or in clinical development for BCBMs.

Turning cold tumors hot: emerging immunotherapies for BCBMs

Mediators of the BCBM immunosuppressive tumor microenvironment

Cancer cell extravasation and colonization in the brain parenchyma is accompanied by a strong local inflammatory response involving activation of astrocytes and microglia [16]. Metastatic cells—through various factors including cytokine or exosome secretion, and changes in gene expression—recruit and educate immune cells to generate a brain tumor microenvironment (TME) conducive to
micrometastasis outgrowth [17]. The BCBM TME consists of several cell types including a variety of immune cells, fibroblasts, endothelial cells, astrocytes, neurons, and tumor cells all physically sequestered by the BBB (Fig. 1A) [17]. As BMs grow, the BBB is remodeled to become a more permeant blood-tumor barrier (BTB) (Fig. 1B), resulting in further infiltration of peripheral immune cells and eventual development of an immunosuppressive TME that shuts off anti-tumor activity [18]. Thus, the key players in establishing and maintaining this TME are largely the targets of current IT strategies. While the growing complexity of the immune system’s role in BCBM is beyond the scope of this review, an overview of the mechanisms by which tumor and immune cells establish an immunosuppressive TME (Fig. 2) is necessary for addressing the therapeutic targeting thereof and is addressed briefly here.

Tumor cells

Upon micrometastasis outgrowth within the brain, tumor cells counteract endogenous neuroinflammatory responses by progressively reprogramming cells within the TME into immunosuppressive phenotypes, as occurs in chronic inflammatory conditions [19]. Real-time multiphoton laser-scanning microscopy tracking the fate of actively metastasizing cells deep in the live brain has demonstrated that metastatic colonization of the brain happens in perivascular sites along the microvasculature [20]. Known as vascular co-option, this

---

**Fig. 1** Breast cancer brain metastases (BCBMs) convert the blood–brain barrier (BBB) into a blood-tumor barrier (BTB). A Breast cancer (BC) cells intravasate at the primary tumor and travel via the circulation to the central nervous system and encounter the intact BBB, consisting of endothelial cells lining the vascular lumen, tightly arranged pericytes, a basement membrane composed of mostly collagen-bundles, and end feet processes projecting from adjacent astrocytes. B BC cell extravasation across the BBB induces an acute local inflammatory response involving activation of astrocytes and microglia, promoting BC cells to adopt several signaling pathways for immune evasion and survival. Surviving BC cells progress into BCBMs, resulting in a transformed BTB with disordered endothelial cells, altered pericyte populations, disruption of the basement membrane, reduced astrocytic end feet, and increased recruitment of immature leukocytes. Some graphics in this figure were adapted from Servier Medical Art (CC BY 3.0 Unported)
likely occurs due to optimal oxygen and nutrient supply; however, it also enables interaction with infiltrating bone marrow-derived cells from the peripheral circulation [21, 22]. These immature immune cells, together with several tumor-derived factors, play a major role in the formation of a PMN that is conducive to metastatic cell immune evasion, colonization, and outgrowth [19, 23]. The mechanisms governing PMN formation are still poorly understood; however, the ability to reprogram anti-tumor TMEs to a pro-metastatic environment has been proven to be a necessity for micrometastasis progression into macrometastases [24–26]. In one study, it was found that BC cells upregulate genes, including SEMA4D, that protect tumors cells from oxidative stress induced upon crossing the BBB and also disable subsequent immune microenvironment activation [27]. Here, the authors showed that c-Myc, which upregulates free-radical scavenging proteins including GPX1 [28], is overexpressed by metastatic cells to resist oxidative stress caused by activated immune cells. In another study, Wingrove et al. used an optimized RNA-seq pipeline called BM xenograft-RNA sequencing (BMX-seq), an approach that leverages xenograft transcriptomes for distinguishing tumor and stromal cell gene expression, to reveal an upregulation of neuronal differentiation pathways within tumor cells as they adapt to

![Figure 2](https://example.com/image.png)

**Fig. 2** Mechanisms of immunosuppression in the BCBM tumor microenvironment (TME). Breast cancer cells establish reciprocal communication with cells within the premetastatic niche, including resident astrocytes, and establish an immununospressed TME conducive for metastatic outgrowth. Tumor-associated macrophages (TAMs) in BCBMs include resident microglia (TAM-MG) and infiltrating bone marrow-derived macrophages (BMDM, TAM-BMDM). Tumor cells secrete factors that promote repolarization of TAMs to M2-like phenotypes that suppress T cell anti-tumor response. cGAMP cyclic guanosine monophosphate-adenosine; cGAS cGAMP synthase; CSF1 colony-stimulating factor 1; CSF1R colony-stimulating factor 1 receptor; CTLA-4 cytotoxic T lymphocyte associated protein 4; FasL Fas ligand; IFNα interferon-α; IRF interferon regulator factors; MIF macrophage migration inhibitory factor; mTORC1 mammalian target of rapamycin complex 1; PD-1 programmed cell death receptor 1; PD-L1 programmed cell death ligand 1; PI3K phosphoinositide 3-kinase; sFasL soluble Fas ligand; STAT3 signal transducer and activator of transcription 3; STING stimulator of interferon genes; TNF tumor necrosis factor; tPA tissue plasminogen activator. Some graphics in this figure were adapted from Servier Medical Art (CC BY 3.0 Unported)
the brain through reciprocal communication with stromal cells [10].

The brain’s reversible upregulation of neuronal differentiation pathways within metastatic cells has also been reported by others. For example, metastasizing BC cells were recently shown to adapt to the unique metabolism of the brain, in part, by mimicking neuronal cells via upregulation of GABAergic genes such as glutamate decarboxylase 1 (GAD1) [29, 30]. This enables metastatic cells to utilize glutamate as an energy source, which is prevalent in the brain. Tumor cells have also been shown to co-opt leukocyte phenotypes to establish BCBMs. For example, tumors upregulate cathepsin S, a protease involved in antigen processing by antigen-presenting cells (APCs), for proteolysis of junctional adhesion molecules and BBB transmigration [31]. Finally, elevated protocadherin7 (PCDH7) expression has recently been detected in patient-derived BCBM samples and in animal models, and has been shown to contribute to BCBM growth by mediating paracrine signaling between tumor cells and astrocytes [32, 33].

### Neuronal cells

Neurons are the main signaling units of the brain, and though not currently implicated in BCBM progression or associated immune responses, neuronal cell death increases due to reduced vascular perfusion caused by compressive and mechanical stress of growing BCBMs [34]. There has been little exploration into the role of neurons in BM progression; however, protecting neural circuitry will remain an important safety consideration for IT.

### Astrocytes

Accounting for ~50% of healthy human brain cells, astrocytes are glial cells that, similar to macrophages, exist within a spectrum of phenotypic and functional polarization states that aid in diverse homeostatic brain processes including immune responses [35]. Also mirroring macrophages, it appears astrocytes may initially inhibit metastasis but begin to progressively facilitate BCBM growth into macrometastases [36]. Astrocytes can initially prevent metastatic colonization by inducing FasL-mediated tumor cell death [34, 36]. Tumor cells, in turn, escape pro-apoptotic signals through increased serpin expression, which inhibits tissue plasminogen activator (tPA) from astrocytes and prevents active plasmin necessary to convert FasL into sFasL. In contrast to this neuro-protective function, more evidence is mounting that suggests astrocytes promote BCBM colonization and outgrowth [12, 37]. For example, it was shown that gap junctions between tumor cells and astrocytes foster tumor cell proliferation and can protect tumor cells from chemotherapy [38]. It was later shown that tumor cells transfer cGAMP to astrocytes through these gap junctions, resulting in astrocyte cGAS-STING-mediated IRF activation, and subsequent secretion of tumor-supportive IFN-α, TNF, and TGF-α [33] (Fig. 2). These gap junctions are thought to facilitate contact in early metastasis, as only tumor cells at the tumor-stromal border are in direct contact with astrocytes later in metastatic outgrowth [38].

Importantly, astrocytes have also been shown to be integral to the immune response to BCBMs. Recently, it was shown that STAT3+ astrocytes in BCBM clinical samples and mouse models promote BCBM growth via expression of immunosuppressive proteins, including PD-L1, and inhibition of CD8+ T cell infiltration [36]. Further, the authors demonstrated that these STAT3+ astrocytes are the source of macrophage migration inhibitory factor (MIF), which contributes to immunosuppressive TAM phenotypes by binding CD74 receptors expressed by TAMs. The drug silibinin, a STAT3 inhibitor, is being studied for targeting these signaling axes in BMs [39].

### Macrophages and microglia

Macrophages are a heterogenous group of myeloid-lineage innate immune cells that originate from differentiation of infiltrating bone marrow-derived monocytes (BMMs) or from proliferation of tissue-resident macrophages that seed distinct organs during embryonic development [40, 41]. Thus, BCBM tumor-associated macrophages (TAMs) include infiltrating BMMs (TAM-BMM) and tissue-resident microglia (TAM-MG). The data on these populations is considerably lacking, as most investigations on TAMs in TNBC have focused on primary tumors, or more recently, on BC lung metastases. Sometimes referred to as metastasis-associated macrophages (MAMs), these BMMs have been shown to assist in cancer cell extravasation and subsequent growth into lung metastases [42, 43]. A recent RNA-seq study indicated that stromal cells specifically within BCBMs, as opposed to stromal cells in bone or lung BC metastases, exhibit the most pronounced gene expression changes compared to the corresponding normal tissue. Indeed, ~54% of the differentially upregulated genes correspond to the gene signature of activated microglia [27], implying that some TAM-targeting strategies may be more suitable for BCBMs than that of other extracranial metastases. While only recently has it been possible to distinguish TAM-BMM and TAM-MG [40], prior studies reveal that both populations display a range of phenotypic and functional differences based on their context-specific polarization state [44].

Although studies categorizing macrophage populations into M1-like or M2-like phenotypes are overly simplistic, the general consensus is that M1 macrophages are pro-inflammatory and generally inhibit tumor growth while
M2 macrophages are tolerogenic and suppress anti-tumor activity [45]. Metastatic cells actively reprogram both TAM-BMDM and TAM-MG to adopt an “M2-like” phenotype, which promotes brain tumor progression through various mechanisms that collectively suppress T cell anti-tumor activity [46, 47]. Indeed, comparison of TAMS in primary tumors versus BCBMs shows significantly higher M2-like gene expression pattern by TAMS in the BCBM TME [44]. A 2010 investigation into the role of microglia in BCBMs confirmed that TAM-MG promote BCBMs by establishing a PMN prior to tumor colonization and act as a guide rail for invasive tumor cells, the latter of which is dependent on Wnt signaling [48]. Importantly, the authors of this study demonstrated that pro-tumorigenic microglia could be repolarized to an anti-tumor phenotype, which underlies therapeutic strategies seeking to re-educate TAMs to a tumoricidal polarization state.

Interestingly, nicotine was recently implicated in TAM-MG skewing to M2-like polarization states in lung BMs [49], necessitating clarification if nicotine has the same effect in BC patients. Nonetheless, these findings challenge a 2006 study reporting that microglia have the capacity to suppress lung BMs [46], which originally posited an anti-tumor role for TAM-MG due to their initial activation and release of pro-apoptotic signals in response to invading tumors cells. Reports from the last decade have clarified these findings and overwhelmingly suggest that both TAM-MG and TAM-BMDM primarily foster BC intracranial metastasis: tumor cells quickly evade microglia-derived apoptotic signals by exploiting tissue damage response pathways to repolarize TAM-MG to tumor-supportive phenotypes [50]. For example, Xing et al. recently demonstrated that metastatic BC cells secrete exosomes containing miR-503 (Fig. 2), which promotes the upregulation of programmed death ligand-1 (PD-L1) and other M2-like markers in TAM-MG, resulting in suppression of T cell proliferation [51]. Collectively, these findings challenge the notion that BCBMs are poorly infiltrated by immune cells—TAMS have since been identified as the most abundant non-tumor cell type in BCBMs [44]—and highlight the potential for therapeutic targeting immunosuppressive TAMs. Several such strategies under clinical and preclinical evaluation are discussed in subsequent sections.

**T cells**

Tumor-infiltrating lymphocytes (TILs), the greatest enforcers of anti-tumor immunity, are present in BCBMs and primarily consist of helper CD4+ and cytotoxic CD8+ T cells [52]. In contrast, bone marrow sequestration often prevents T cell accumulation in primary brain tumors [52]. In fact, in one of the largest retrospective analyses of human BCBMs, CD4+ and CD8+ TIL infiltration was observed in 96% and 98% of cases, respectively, compared to macrophages/microglia observed in 92% of cases [53]. The density of CD8+ TILs was also comparable to that of CD68+ macrophages/microglia; however, there was no correlation between TIL accumulation and overall survival (OS) [53]. This suggests that CD8+ TILs, while capable of trafficking to BCBMs, become exhausted and/or dysfunctional upon encountering the immunosuppressive TME discussed above. In contrast to TIL accumulation, programmed death 1 (PD-1) expression on TILs was independently associated with OS, further suggesting the importance of an activated immune response [53]. PD-1 and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) are both inhibitory receptors expressed by T cells that function as negative feedback loops upon T cell activation in order to maintain immune homeostasis and prevent autoreactivity [54]. While both receptors are essential for maintaining tolerance by counteracting T cell costimulatory signaling under chronic inflammatory conditions, such as in tumors, T cells become exhausted and upregulate these and other inhibitory receptors to inhibit T cell activation, proliferation, survival, and production of IFN-γ, TNF-α, and IL-2 [55]. Consequently, inhibiting these receptors with antibodies has been shown to enhance anti-tumor T cell activity [56] and several clinical trials are underway to evaluate the efficacy of anti-CTLA-4 and anti-PD-1 therapies in BCBMs (Table 1). While there is clear evidence that T cells do infiltrate BCBMs, comparative analyses of intratumoral CD4+ and CD8+ TILs in BC patients show lower accumulation of TILs in BMs compared to extracranial metastases [57] or primary tumors [58, 59], suggesting that ITs that enhance T cell trafficking to BCBMs may also be a valid strategy for enhancing efficacy.

Not all T cells, however, are effectors of anti-tumor immunity. CD4+ regulatory T cells (Tregs) are critical mediators of immune tolerance through suppression of several immune populations, including other T cells and dendritic cells (DCs) [60]. This suppressive function of Tregs is also exploited by tumors as a means to inhibit anti-tumor responses [61]. A 2009 study used ultrasonic tumor aspirates to analyze immune infiltration in brain tumors from 83 patients [62]. The investigators used a suction adaptor to collect aspirated tumor fragments, a technique that is routinely utilized for biopsy of other solid tumors [63] and has since been validated as a sterile biosource for tissue culture studies in gliomas [64], and showed massive Treg infiltration that strongly suppressed TIL function. In fact, they showed that patients with BMs, regardless of the primary tumor, exhibit even higher levels of intratumoral Tregs than that of primary brain tumor patients, signifying Treg recruitment as a general characteristic of BMs. These results suggest that peripheral Tregs in patients with BMs can potentially be targeted to prevent BM accumulation. Further supporting such
a strategy, Tregs have also been shown to exhibit increased accumulation as BMs progress [65, 66].

**Other immune cells**

Our understanding of the BCBM TME and its interaction with the immune system is still in its infancy and will require further study to fill the large gaps of data regarding the potential of IT for BCBM treatment. Investigation into other immune cell players in BCBMs has been lacking. To date, there have been no studies investigating the interaction of APCs and TILs that may contribute to a BCBM anti-tumor response, and there is also a scarcity of data concerning the role of neutrophils or natural killer (NK) cells in BCBM pathology [45]. Neutrophils have been shown to accumulate in the BCBM pre-metastatic niche and support tumor cell seeding [67], whereas NK cells were recently implicated in metastatic evasion of immune surveillance, both of which can be targeted to reduce metastatic seeding [68]. Increased investigation into IT for BCBMs, however, will hopefully elucidate the relevance and contribution of these important immune players.

### Current immunotherapy strategies for brain metastasis treatment

Immunotherapeutic approaches can be broadly classified as those that (1) inhibit immunosuppression to release the brakes on anti-tumor immunity and/or (2) enhance immune responses to stimulate anti-tumor activity. Owing to the
traditional notion that BCBMs are poorly immunogenic, most clinical trial and preclinical studies to date have assessed IT for melanoma and non-small cell lung cancer (NSCLC) BMs [69]; however, IT studies in the context of BCBMs are beginning to emerge and are reviewed below.

**Immune checkpoint inhibitors (ICIs)**

Checkpoint blockade involves use of ICIs targeting immune checkpoint proteins, including PD-1 and CTLA-4 inhibitory receptors expressed by T cells, as well as PD-1 ligands 1 and 2 (PD-L1, PD-L2) expressed by stromal and tumor cells. Cancer cells co-opt these tolerogenic signaling axes in order to counteract the neuroinflammation induced upon BC micrometastasis [70] and to evade recognition and elimination by T cells. ICIs currently include monoclonal antibodies (mAb's) against PD-1 (nivolumab, pembrolizumab, cemiplimab), PD-L1 (atezolizumab, avelumab, durvalumab), and CTLA-4 (ipilimumab, tremelimumab) (Table 1). Because these BCBM clinical trials have just recently begun, the promise of exploiting these signaling axes for BCBM treatment primarily comes from ICI efficacy reported in BMs originating from lung tumors or melanomas [71]. In a 2019 retrospective study of 271 patients with lung or melanoma BMs receiving SRS, for example, median OS of patients receiving ICIs was 15.9 months compared to just 6.1 months for those who did not receive ICI treatment [72]. Subsequent use of combination therapies increased ICI efficacy, with combination of ipilimumab and nivolumab increasing response rates in melanoma patients to 50–55% [73, 74] compared to that of ipilimumab monotherapy, which had response rates of 16–25% [75]. CTLA-4 and PD-1 are thought to be involved in the early priming and effector phases of T cell activation, respectively, and thus this combined ICI strategy is thought to provide additive efficacy in these patients by modulating temporally distinct components of T cell responses. However, safety remains an important limitation in combined ICI strategies, as 96–97% of patients receiving dual ICI therapy experienced adverse side effects compared to just 68% in nivolumab monotherapy trials [76].

The utility of ICI for BCBMs remains poorly understood due to the exclusion of patients with metastatic BC from most ICI clinical trials if they are also harboring BCBMs. Recently, however, a pilot study of tremelimumab (CTLA-4 mAb) with radiation was completed to determine the abscopal effect and impact on non-CNS disease control in 20 Her2- and 6 Her2+ patients with BCBMs [77]. While the effect of this regimen on BCBM progression was not specifically evaluated, this trial did assess the safety of tremelimumab with trastuzumab (Her2 mAb) and radiation in Her2+ disease, which was well tolerated. Despite the removal of 42% of patients from the study due to rapid non-CNS disease progression or death within 12 weeks, this trial provided important data pertaining to the safety of ICI for patients with BCBMs.

**TAM and microglia-targeted therapies**

In addition to ICI, several promising TAM-targeting strategies are being investigated for BCBMs. The phosphoinositide 3-kinase (PI3K) pathway, which is activated in over 70% of BCBMs [78, 79], plays a central role in the metastasis-promoting functions of TAM-BMDM and TAM-MG, in part, by upregulating their expression of immunosuppressive genes including PD-L1 and the colony-stimulating factor (CSF) 1 receptor (CSF1R) [80]. Further, pharmacological inhibition of PI3K in infiltrating TAMs with BKM120 (buparlisib), a class I PI3K inhibitor with good BBB penetration [81], resulted in repolarization of TAMs to a more anti-tumor phenotype and reduced BC infiltration into brain parenchyma [80]. In an earlier study, oral administration of BKM120 in several Her2+ multi-organ metastasis models led to a strong reduction in BCBM tumor burden [82], showing promise for further studies of PI3K inhibition in BCBMs. BKM120 recently completed a phase II clinical trial in combination with the chemotherapy capecitabine in BCBM patients (NCT02000882); however, the results have yet to be published.

Activated PI3K signaling also leads to downstream activation of the protein kinase B (also known as Akt) and mechanistic target of rapamycin (mTOR) pathways, both of which are implicated in the progression of various cancers including BC. There are several drugs targeting crucial components of these pathways; however, only a few are in clinical trials for BCBMs. Everolimus (RAD001) is a mTOR complex 1 (mTORC1) inhibitor with BBB penetrating capability [83] that was approved for advanced HR+ BC patients in combination with aromatase inhibitors in 2012 following the BOLERO-2 trial [84]. Despite the exclusion of patients with BCBMs or CNS-specific responses from the BOLERO-2 trial, everolimus in combination with trastuzumab and vinorelbine is currently in a phase II clinical trial for Her2+ patients with BCBMs (NCT01305941). Other mTORC1 inhibitors, such as tesirolimus, are also under active investigation in preclinical BCBM models [85]. Dual PI3K/mTOR inhibitors including BEZ235 [86] (NCT014952247, NCT01300962), XL765 [85, 87], and GDC-0084 (NCT01547546) are under preclinical and clinical development in gliomas, and recent data suggests such dual blockade has promise in Her2+ BCBMs [88]. Using orthotopic patient-derived xenografts (PDXs) of Her2+ BCBMs, Ni et al. showed that combined inhibition of PI3K and mTOR with BKM120 and everolimus results in durable tumor regression [88].

There is also an increasing number of TAM-targeting strategies emerging in preclinical studies. The CSF1/CSF1R
Anti-CD3 and anti-Her2 bispecific antibodies were used in a phase I clinical trial of 23 patients with Her2+ metastatic breast cancer, showing promise for improving outcomes for BCBM patients. Indeed, ACT likely holds durable regression of untreated BMs [99]. Based on these observations in non-breast BMs, ACT protocols typically require 4–6 weeks of TIL expansion in culture to obtain adequate numbers of reactive lymphocytes, which are then transferred back into the patient with or without lymphodepletion regimens and/or concurrent interleukin 2 (IL-2) infusion (Fig. 3A). While ACT has been shown to induce durable clinical responses in multiple clinical trials [98], ACT protocols typically require 4–6 weeks of TIL expansion in culture to obtain adequate numbers of reactive T cells for reinfusion [99]. Despite these practical limitations, a retrospective study of 26 patients with melanoma BMs receiving ACT with autologous or TCR-transduced TILs demonstrated that activated lymphocytes could not only traffic to the CNS but can also mediate complete and durable regression of untreated BMs [99]. Based on these and other observations in non-breast BMs, ACT likely holds promise for improving outcomes for BCBM patients. Indeed, in a phase I clinical trial of 23 patients with Her2+ metastatic BC, eight infusions of polyclonal activated T cells transduced with anti-CD3 and anti-Her2 bispecific antibodies (Her2Bi), termed armed ACT (aACT) [100], successfully induced anti-tumor responses and were safe in patients with visceral metastases [101]. This strategy is currently being evaluated using intraventricular administration for patients with Her2+ leptomenigial BCBMs (NCT03661424).

Adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells is another form of ACT that has yielded exciting results for the treatment of solid cancers. Though CAR T cell designs vary, a recent study by Priceman et al. demonstrated Her2-targeted CAR (Her2-CAR) T cells containing 4-1BB intracellular costimulatory domains reduced T cell exhaustion and enhanced proliferative capacity compared to those containing CD28 for costimulation [102]. When evaluating the efficacy of these Her2-CAR T cells in human PDX BCBM models, however, efficacy could only be achieved following local delivery. The authors show that local Her2-targeted CAR T cell therapy results in complete BCBM regression following intracranial delivery, but intravenous (IV) delivery of tenfold greater doses of CAR T cells results in only partial BCBM tumor regression. These results suggest that, despite Her2-targeting, ACT for BCBMs is not quite feasible with systemic drug delivery due to barriers in T cell BCBM trafficking [102]. Regardless, several clinical trials are underway to evaluate the safety, recommended dosage, and efficacy of intraventricularly-administered CAR T cells for BCBMs (NCT03696030, NCT03661424) (Table 1).

Vaccines

Cancer vaccination has taken many forms; however, most involve DCs, which are professional APCs that capture and present antigens to T cells for activation. While most studies have focused on the effects of DCs in glioblastoma patients [103], long-term complete remission has been achieved in patients with melanoma BMs following autologous tumor lysate-loaded DC vaccination and RT [104]. With the recognition that BC is indeed an immunogenic disease, multiple BC tumor-associated antigens (TAG's), including Her2 and mucin 1 (Muc1), are being explored for potential vaccines for patients with extracranial BC tumors [105, 106]. Several clinical trials will help to elucidate the utility of DC vaccines for patients with BCBMs (NCT02808416, NCT01782274), including an ongoing phase I trial investigating the autologous, tumor lysate-pulsed DC vaccine DCVax-Direct (NCT03638765).

Radiotherapies to increase immunogenicity

For patients with non-resectable BMs, RT remains the standard of care treatment with WBRT typically indicated for patients with multiple metastases and SRS for those with fewer metastases. RT has long been shown to enhance immunogenicity, and therefore, RT is also being explored.
as a strategy to sensitize the TME for IT by inducing immunogenic cell death (ICD), which increases tumor mutational burden, major histocompatibility complex I (MHC I) expression, and secretion of inflammatory cytokines [107]. RT ICD is mediated, in part, by a cytosolic DNA pathogen recognition receptor (PRR) capable of initiating anti-tumor responses against tumor-derived DNA. Mechanistically, RT-induced DNA damage activates cGAS, resulting in cyclic GMP-AMP (cGAMP) release and subsequent activation of stimulator of interferon genes (STING) and downstream production of inflammatory cytokines [108]. RT is also particularly of interest in combination with IT due to the abscopal...
effect, which refers to anti-tumor responses outside of the radiation field. Indeed, the combination of SRS with IT prolongs survival in patients with melanoma BMs [109–111], and several clinical trials, including a pilot studying evaluating CTLA-4 and PD-L1 inhibition with RT (NCT02563925), are ongoing in BCBM patients (Table 1). In a single phase I prospective clinical trial combining RT + ipilimumab in patients with melanoma BMs (NCT01703507), ipilimumab in combination with either SRS or WBRT was safe; however, it failed to demonstrate efficacy of either combinatorial treatment [112]. In that trial, 14 of 16 patients had disease progression and/or had died during the follow-up, demonstrating combined RT + IT is still in an exploratory phase and requires further study to validate the efficacy of this combination strategy.

**Challenges to BCBM immunotherapy**

The data summarized above demonstrates the presence of an activated immune response in BMBMs and implies that IT has great potential for treatment of patients with BCBMs. However, despite the approval and use of several IT treatments in various cancer settings, there remain several specific and unique limitations to IT for BCBMs that are summarized below.

**The blood-tumor barrier (BTB) and other challenges to intracerebral IT drug delivery**

Drug delivery of most systemic chemotherapeutics to BMs is limited by the BBB, which regulates and severely restricts the movement of molecules from the systemic circulation and into the brain parenchyma. The major cellular components of the BBB include endothelial cells connected via tight junctions, pericytes lining the capillary surface, and astrocytes with their end feet projections (Fig. 1) [9]. The BBB is remodeled to a BTB upon BM outgrowth, consisting of neuroinflammatory endothelial cells and altered pericyte populations, which continues to restrict most cytotoxic agents and drugs from crossing into the brain (Fig. 1B) [113]. Though the BTB is considered to be slightly more permeable than the BBB [114], MRI findings have shown that the BTB does not exhibit elevated permeability in all patients [115, 116], particularly those with Her2+ BMs [117]. The median ratio of trastuzumab levels in the serum and cerebrospinal fluid (CSF) of Her2+ BC patients, for example, was found to be 420:1 [113], which could be improved to 76:1 upon co-treatment with RT. Studies following up on this data reported that trastuzumab-treated Her2+ BC patients have higher incidence of BM development due to a lack of intracranial control of the disease [118]. Endothelial cells comprising the BTB still retain elevated trans-endothelial electrical resistance and large numbers of efflux pumps, which limit paracellular and transcellular drug transport, respectively. As a result, generally only drugs that are lipophilic and have a low molecular weight have efficient transport across the BTB [119], representing a significant barrier to all systemic BCBM therapies, including IT agents.

Even lapatinib, a small molecule inhibitor of Her2 and epidermal growth factor receptor (EGFR) tyrosine kinases that was presumed capable of crossing the BBB, has poor BBB penetration: the average accumulation of lapatinib in BMs was just 10–20% of that of peripheral metastases in mouse models of experimental BMs [120]. Lapatanib has also shown limited activity against human BCBMs [121], underscoring the need for strategies that improve BM penetration. Interestingly, however, combination of capecitabine and lapatinib improved patient response rates [121], suggesting lapatinib acts in a synergistic manner. More recently, evaluation of systemically administration trastuzumab emtansine (T-DM1) has begun in patients with Her2+ BCs [122–124]; however, the penetration of systemically administered IT remains to be studied.

Several other factors in addition to the BTB impede drug delivery to BCBMs. In particular, the brain’s dense, anisotropic, and electrostatically charged extracellular space, combined with elevated interstitial pressure, further limit convective and diffuse drug transport in BMs [125]. Transport is further inhibited by the brain’s glial lymphatic system, which promotes rapid drug clearance from the brain, as well as upregulated expression of multidrug resistance pumps [126]. Such transporters, which include BC resistance protein and P-glycoprotein, contribute to development of resistance, yet another barrier to BCBM drug delivery. Indeed, recent clinical studies have emphasized that even drugs capable of crossing the BTB for Her2+ BCBM treatment still do not provide a significant therapeutic benefit due to resistance mechanisms [127]. Collectively, these limitations to BCBM drug delivery prevent the efficacy of potential ITs and confounds the potential of such strategies. As new strategies to enhance IT and systemic drug delivery emerge, it will also be important to consider how these restrictions to intracranial drug delivery may restrict TIL infiltration into BMs, which has yet to be investigated.

**Limited molecular targets for BCBM IT**

The identification of driver mutations and overexpressed proteins in tumors and the subsequent development of drugs targeting these axes have transformed the oncology community over the past decade [128]. While several inhibitors targeting Her2, vascular endothelial growth factor (VEGF), PI3K/mTOR, and EGFR pathways are under investigation for metastatic BC patients, the initial trials investigating their use excluded patients with BCBMs and thus have
significantly limited the progress of such strategies for these patients [128]. This has led to a paucity in feasible targets for BCBM therapy, and thus there is a clear demand for identification of more effective targeted therapeutics. Utilization of targeted therapeutics is relevant to BCBM IT strategies for two major reasons. First, targeted delivery of chemotherapeutics or other drugs increases ICD, thereby potentially sensitizing tumors for IT intervention [107, 108]. Indeed, combinatorial approaches utilizing chemotherapies to induce ICD prior to ICI therapy result in superior tumor control than either monotherapy alone [129]. Second, identification of novel targets for BCBMs can be utilized for the development of more efficacious ITs. Tumor cell–targeted NPs, for example, can be utilized as IT drug delivery portals for BCBMs. The utility of such strategies, however, remains limited by the number of actionable targets identified for BCBMs.

Safety considerations for BCBM IT

The utility and development of IT for many cancers were perhaps most limited initially by substantial safety concerns. High-dose IL-2, an important cytokine for TIL activity, was among the first ITs studied in cancer patients and, aside from its dismal response rates, caused serious adverse effects (AEs), including death [130]. ITs that have followed IL-2 therapy, including ICIs, have only recently begun to incorporate patients with intracranial tumors in safety trials. ICIs generally cause similar immune-related AEs regardless of tumor type, which most commonly affect the endocrine and gastrointestinal systems, skin, and liver [131].

In regard to BMs specifically, investigations into ICI safety have mostly been in patients with melanoma or lung BMs [132, 133]. ICIs as monotherapies have generally been well tolerated in these patients, leading to their approval [69]. Combinatorial ICI treatment, however, has been associated with increased AEs: nivolumab + ipilimumab combination, though more efficacious, was found to cause grade III or IV AEs in 54% of patients, compared to 16% of those receiving nivolumab alone [74]. Despite the discontinuation of ~27% of patients, combination ICI was otherwise well tolerated by the majority of patients, suggesting more research is necessary to clarify why some patients experience AEs and others do not. ACT also comes with significant safety concerns, with unexpected organ damage, neurological toxicities and death in early human studies infusing patients with engineered and/or CAR T cells [134]. Toxicities of CAR T cell therapies are numerous and include cross-reactivity against normal cells and immune over-activation, the latter of which can occur through cytokine release syndrome (CRS). The substantial safety considerations of CAR T cells are just beginning to be understood and are reviewed elsewhere [135], but it is also worth mentioning that the complex procedure of engineering human T cells in the lab introduces additional potential safety concerns (Fig. 3A). Several ongoing clinical trials in BCBMs will inform on the safety of these and additional IT strategies for these patients.

Harnessing nanomedicine for BM immunotherapy

Nanomedicine for BCBMs

Nanomedicine is a rapidly expanding field and represents a particularly advantageous strategy for enhancing the delivery, safety, and efficacy of ITs for BCBMs. The therapeutic value of nano-oncology resides in the ability to fine-tune physiochemical properties including size, shape, surface charge or targeting of nanotherapeutics (Fig. 4). Further, the characteristically high ratio of NP surface area to volume enables use of multiple surface modifications simultaneously for a given NP, such as conjugation to multiple targeting moieties. In addition, use of NPs can greatly improve drug pharmacokinetics and solubility while simultaneously preventing side effects in patients due to encapsulation of a given drug. The same NP can be modified for encapsulation of different payloads for context-specific use, and furthermore, use of NPs also offers the opportunity for controlled drug release at tumor sites. For example, physiological variables (pH, temperature, redox status) and non-physiological variables (light, ultrasound, electromagnetics) can facilitate the release of concentrated NP payloads within tumors in response to tumor-specific stimuli [136]. Numerous different kinds of NP therapeutics exist, including polymers, micelles, and liposomes, though only two of these are currently in clinical trials for BCBM patients (Table 2).

Generally, NP accumulation in tumors is driven by passive or active targeting. The former generally relies on the “enhanced permeability and retention” (EPR) effect in which leaky blood vessels and dysfunctional lymphatics promote NP delivery to tumors [137], whereas active targeting involves conjugation of tissue- or cell-specific targeting moieties to NP surfaces [138]. EPR-mediated tumor accumulation ultimately led to the development of Doxil and Abraxane, NP formulations of the conventional chemotherapies doxorubicin and paclitaxel, respectively, which are FDA-approved for metastatic BC [139]. It is presently unclear if BMs exhibit an EPR effect for passive nanomedicine accumulation. Recent work by Sinwhwani et al. addressed the mechanisms of NP entry into tumor tissue. Using a combination of transmission electron microscopy (TEM), 3D imaging, computational analysis, and a “Zombie” mouse model that allows for distinction between passive gap and active trans-endothelial transport, this group showed that targeted NPs consistently accumulate in tumors via active
Fig. 4 Design and engineering considerations for nanoparticles (NPs). Several types of nanoformulations exist that can be broadly classified as organic or inorganic. Examples of organic NPs include dendrimers, liposomes, micelles and polymeric NPs, while inorganic NPs include gold NPs, iron oxide NPs, and quantum dots. NPs can also be classified based on their physicochemical characteristics, such as NP shape, size, and surface charge. Surface modifications of NPs include use of targeting moieties for specific cellular or tissue localization, as well as modifications that minimize recognition and clearance by the immune system such as PEGylation or use of protein corona shields on NP surfaces. NPs can be designed for delivery of various cargo including small molecules, plasmid DNA, mRNA, and proteins. Encapsulated cargo can be engineered for specific release profiles, and even for controlled release in response to changes in temperature, pH, or application of an external magnetic field.

Table 2 Nanotherapeutics currently in clinical trials for BCBMs

| Drug/therapy name                  | Nanotherapeutic type | Cancer subtype/inclusion criteria | Phase | # of pts | NCT identifier   |
|-----------------------------------|---------------------|-----------------------------------|-------|----------|------------------|
| NaI-IRI                           | Liposome            | BCBMs                             | II    | 63       | NCT03328884      |
| Pyrotinib, Trastuzumab + Abraxane | Albumin NPs         | Her2+ BCBMs                       | II    | 100      | NCT04639271      |

https://clinicaltrials.gov/. Accessed January 3, 2021

BCBMs breast cancer brain metastases; Her2 human epidermal growth factor receptor 2; NaI-IRI nanoliposomal irinotecan; NPs nanoparticles; pts patients
trans-endothelial transport mechanisms such as receptor-mediated uptake and vesicular transport or passage through transcellular channels [138]. For BCBMNs specifically, NPs are especially poised for improved BTB penetration due to their small size (~100 nm) and the potential for reduced neurological and peripheral side effects due to targeting capability and drug encapsulation. Though recently found to be associated with adverse reactions in some patients [140], systemically administered NPs are often engineered with polyethylene glycol (PEG) on their surface to reduce recognition and clearance by the mononuclear phagocyte system (MPS), further enabling intratumoral accumulation [141]. Until recently, NPs were generally designed with such strategies to reduce immune responses. However, NPs are increasingly being studied for use as ITs themselves or in combinatorial treatment strategies. This work is summarized below.

**Nanomedicine-enhanced immunotherapy**

While many scientists have published their data and perspectives on either immuno- or nano-therapy for BM treatment individually, there is a considerable lack of original data pertaining to nanomedicine-enhanced immunotherapy strategies in BCBMNs specifically. Here, we review current and emerging nanotech strategies for improving IT (nano-IT) for BMs of various primary cancers and their potential for use in BCBM patients specifically. Of these, perhaps the best studied are nanoimmunoconjugates, in which nanostructures are conjugated to antibodies or other targeting moieties to enable more localized IT delivery. Several clinical and preclinical studies are investigating nanoimmunoconjugates targeting (i) the BBB, (ii) tumor cells, (iii) TAMs and myeloid cells, (iv) T cells, and (v) APCs. In addition, use of immune cells as NP carriers and RT to promote ICD are also novel nano-IT strategies in preclinical development.

**BBB targeting and translocation strategies**

Several approaches are under development that harness endogenous transport mechanisms to cross the BBB, including receptor-mediated transcytosis, after systemic administration of NPs [142]. The transferrin receptor (TfR), for example, is of particular interest for intracranial drug delivery due to its high expression on the luminal side of the BBB endothelium [143]. Using three separate tumor inoculation models (intracranial, intracardiac, or intravenous injections), Wyatt et al. demonstrated that systemically administered, pH-dependent mucic acid polymer (MAP) NPs conjugated to camptothecin (CPT, MAP-CPT) (Table 3) can effectively target TfR on the luminal side of the BBB, deliver CPT, and inhibit Her2+ BCBM growth in mice [144]. These NPs also enabled controlled drug release, as pH-responsive portions of the MAP-CPT complex are cleaved due to acidification during transcytosis, releasing CPT into the brain. The same group next assessed the ability of this BBB-targeting MAP delivery system to deliver trastuzumab alone or in combination with CPT [145]. Importantly for IT, which includes ICI therapeutic antibodies, this strategy was feasible for antibody delivery and found that BBB-targeted MAP-CPT-trastuzumab combination NPs result in significantly better tumor control than either therapy alone. Still, NPs with TfR-targeting agents have been shown to remain entrapped in brain endothelial cells or capillaries instead of traveling into the tumor [146, 147], necessitating further investigation into the TfR for BBB translocation.

Another group demonstrated the promise of BBB targeting using iRGD peptides (CRGDK/RGPD/EC), which bind integrins expressed on BBB endothelial cells, and demonstrated that iRGD peptides can be formulated into drug-loaded, tumor-penetrating NPs (Table 3) that are capable of inhibiting BCBM development in two mouse models following a single intravenous injection [148]. More recently, prostate-specific membrane antigen (PMSA) was identified as a potential BBB target, as PMSA is specifically expressed in BCBM-associated endothelial cells, and Ni et al. designed poly (lactic-co-glycolic acid) (PLGA)-poly-L-lysine (PLL)-PEG(PLGA-PLL-PEG) NPs conjugated to ACUPA for PMSA targeting (Table 3) [149]. Furthermore, these NPs were further co-targeted to p32 expressed on BC cells via NP conjugation to cyclic TT1. These dual BBB- and BCBM-targeted NPs not only demonstrated BTB crossing, BCBM inhibition, and prolonged mouse survival, but also the therapeutic benefits of combination therapies. Future BBB-targeting strategies will likely employ further combinatorial approaches. For example, lexiscan-loaded, AMD3100-conjugated, tumor-inducible NPs (LANPs) were recently developed to encapsulate and deliver doxorubicin to BCBM [150]. Lexiscan was used to pharmacologically increase BBB permeability, AMD3100 was utilized to target CXCR4 overexpressed on tumor cells, and a neutrophil elastase (NE)-cleavable peptide was used for controlled drug release at the tumor. The latter is activated by the presence of NE, which is highly enriched in BCMNs. These intricately designed NPs significantly prolonged survival of BCBM-harboring mice, again demonstrating the potential of nanomedicine for fine-tuning drug delivery specifically to BCMNs. To our knowledge, there have been no studies examining the utility of such BBB-targeting for delivering ICIs or other IT agents to BCMNs.

**Targeting tumor cells**

Tumor cell-directed NPs carrying cytotoxic payloads offer the possibility of converting immunologically cold BCBMNs
Table 3  Examples of targeted nanotherapeutics in preclinical investigation for BCBMs

| Schematic | Nanomaterial | Targeting Moiety | Molecular/Cellular Target | Cargo | Reference |
|-----------|--------------|------------------|---------------------------|-------|-----------|
| MAP       | Mucic acid polymer (MAP) | Transferrin (Tf) | Transferrin Receptor (TFR) / BBB endothelial cells | Camptothecin (CPT) | Wyatt et al 2019 |
| IO NW     | Iron oxide (IO) Nanoworms (NW) | iRGD peptides | Integrins / BBB endothelial cells | N/A | Hamilton et al 2015 |
| PLGA-PLL-PEG | poly (lactic-co-glycolic acid) (PLGA)-poly-l-lysine (PLL)-polyethylene glycol (PEG) | 2-(3-(S)-5-amino-1-carboxypentyl)ureido) pentamethiodic acid (ACUPA) & cyclic TT1 | Prostate-specific membrane antigen (PMSA) & p32 / BBB endothelial cells & BC cells, respectively | Doxorubicin (Dox) or Lapatinib (LAP) | Ni et al 2020 |
| HDL-DES-MDEA-PEG | Hexadecanamide (HDL)-diethyl sebacate (DES)-N-methylidethanolamine (MDEA) | Chlorotoxin | MMP-2 / BC cells | Lexiscan and Leucine-rich repeat-containing protein 31 (LRRC31) cDNA | Chen et al 2020 |
| AMD3100   | poly(lactone-co-β-amino ester) (PβAE) | AMD3100 | CXCR4 / BC Cells | proMel | Zhou et al 2020 |
| PLGA-PEG  | poly (lactic-co-glycolic acid) (PLGA)-polyethylene glycol (PEG) | ITEM4 (IT4) monoclonal antibody | Fibroblast growth factor inducible 14 (Fln14) / BC cells & TAMs | Paclitaxel (PTX) | Dancy et al 2020 |

Abbreviations. CTLA-4, cytotoxic T lymphocyte-associated protein 4. CXCR4, CXC chemokine receptor 4. MMP-2, matrix metalloproteinase-2. PD-1, programmed cell death protein 1. TAMs, tumor-associated macrophages.

CTLA-4 cytotoxic T lymphocyte-associated protein 4; CXCR4 CXC chemokine receptor 4; MMP-2 matrix metalloproteinase-2; PD-1 programmed cell death protein 1; TAMs tumor-associated macrophages

© Springer
into immunoresponsive tumors by debulking the tumor site and concomitantly removing biological barriers to T cell infiltration. Further, direct killing of tumor cells by chemotherapeutics promotes ICD via the release of damage-associated molecular patterns and Tag’s from dying tumor cells, which in turn stimulate innate and adaptive immune responses [151]. In that vein, there has been significant interest in engineering NPs that specifically target proteins over-expressed in BCBMs for preferential drug delivery. Similar to BTB-targeting strategies, exploiting active targeting may provide more opportunity for improving the delivery, safety, and efficacy of IT payloads. Her2-targeted NPs are perhaps the most clinically developed of these drug delivery platforms. For instance, Patil et al. developed a tumor-targeted poly(β-1-malic acid) (PMLA)-based nanotherapeutic platform to deliver trastuzumab to HER2+ BMs in vivo. Here, PMLA was chemically conjugated to (i) trastuzumab to specifically target Her2+ BC cells and (ii) TfR mAb to ensure transcytosis through BBB. The NP-treated mice bearing HER2+ BMs demonstrated significant reduction of Her2 and phosphorylated Akt levels, a downstream indicator of Her2 signaling, thereby increasing the survival time by 57% in comparison to PBS treated mice. Their NP platform was also conjugated to leucine ethylester (LOEt) moieties to promote endosomal escape upon intracellular uptake. MM-302, a Her2-targeted PEGylated antibody–liposomal doxorubicin conjugate, is another NP drug delivery system which has been used to specifically maximize doxorubicin delivery to Her2+ tumor cells. Preclinical studies conducted with MM-302 demonstrated superior efficacy against Her2 over-expressing cancers when administered alone or in combination with trastuzumab or cyclophosphamide, respectively [152–154]. While the clinical trial of MM-302 combined with trastuzumab did not show a significant efficacy difference in comparison to control (NCT02213744) and is terminated [155], tumor deposition data using Cu-MM-302 PET/CT reported the distribution of the nanoconjugates to brain metastasis [156] and demonstrates the ability of these NPs to preferentially and specifically accumulate in BCBMs.

Additional targeting strategies for tumor cells, however, are necessary for BMs without Her2 overexpression, and these targets are beginning to be identified in preclinical investigations. One group recently used CXCR4, which is enriched in BCBMs, to target poly(lactone-co-β-amino ester) NPs to tumor cells (Table 3). These intricately designed NPs were used to deliver an artificial gene, proMel, that is activated by MMP-2, which is also enriched in BCBMs [157]. Lapatanib, a dual inhibitor of both Her2 and EGFR, represents another targeting strategy, as EGFR is frequently overexpressed by BCBMs. Wan et al. recently developed lapatinib-loaded human serum albumin NPs (LHNPs) and demonstrated enhanced delivery of the drug to TNBC BMs in animal models, resulting in prevention of metastasis and increased survival time in comparison to clinically approved drug Tykerb [158]. Another group used oleic acid (OA), which was recently shown to self-assemble into NPs, to deliver paclitaxel to primary breast tumors and BCBMs in mouse models [159]. In this unique approach, the authors previously screened natural compounds capable of self-assembly and selected OA based on its known anti-tumor and anti-viral properties, arguing the anti-tumor activity of the OA carrier itself synergizes with that of the cargo for a combinatorial approach to enhance efficacy. This may open a new direction in BM therapeutics aimed at identifying NP carriers that have endogenous anti-tumor activity. Finally, our group has recently designed paclitaxel-loaded, fibroblast growth factor-inducible 14 (Fn14)-targeted PLGA-PEG NPs (Table 3), which outperformed the clinical paclitaxel-NP formulation, Abraxane, in a mouse model of TNBC growth in the brain [160]. Crucially for BMs, these NPs were specifically designed to exhibit Decreased non-specific Adhesivity to brain extracellular matrix and Receptor Targeting, or DART, characteristics [161, 162]. These NPs target Fn14, which is overexpressed in BCBMs as well as various other solid tumors [163] and thus represents a potential delivery platform for IT agents as well.

**Targeting and reprogramming immunosuppressive TAMs**

Owing to both the prevalence of TAMs and their largely immunosuppressive role in tumors, targeting these key stromal cells in BCBMs by nanomedicine is a highly promising strategy. TAMs are reported to non-specifically take up NPs, and indeed much of the literature involving NP uptake by TAMs involves passive TAM targeting [164]. In studies of extracranial murine tumor models, for example, the majority of Her2-targeted gold NPs were taken up by perivascular TAMs and not by Her2+ cells [165]. TAMs therefore potentially represent a non-selective NP sink, which can be hijacked to deliver agents that promote TAM repolarization to an anti-tumor phenotype. Iron oxide NPs (IONPs), in particular, have been shown to inhibit tumor growth by repolarizing TAMs to pro-inflammatory phenotypes in preclinical BC models [166]. In the case of IONPs, repolarization is based on the NPs themselves as opposed to delivery of an immunomodulatory agent. Recently, tandem peptide nanocomplexes (TPNCs) carrying CpG DNA (TLR9 agonists), which stimulate TAM inflammatory gene expression, were shown to suppress tumor growth and synergize with CTLA-4 inhibition in primary BC models [167], warranting investigation of this strategy for BCBMs.

TAMs have also been studied in the context of active NP targeting for selective cell depletion. Liposomal NPs were recently employed to eliminate TAMs in preclinical BCBM models, wherein intracerebral injections of mannoseylated clodronate liposomes resulted in a significant reduction of
tumor burden (Table 3) [168]. Another group identified a unique peptide sequence, M2pep, that preferentially binds to M2-polarized TAM populations [169]. This targeting moiety was subsequently used for nanodelivery of CSF-1R siRNA to TAMs in melanoma mouse models and resulted in a significant inhibition of tumor growth [170]. In another study, BG34-10 glucan was identified to mediate specific and active internalization of NPs by primary macrophages [171], and was able to effectively deliver MIF siRNA to TAMs within 4T1 mammary tumors and reduce their MIF expression following systemic administration. While preclinical investigation of M2pep- or BG34-10-glucan-targeted NPs for BCBMs is clearly warranted, these TAM-targeting strategies underscore the increased safety afforded by nanomedicines, as these NPs are internalized by intratumoral TAMs and exhibit minimal uptake by tissue-resident macrophages in the liver, spleen, kidneys, or lungs. NP delivery of ICIs is another potential avenue for TAM targeting; however, this has yet to be investigated in BCBMs.

**Targeting T cells**

Perhaps the greatest limitations to engineered and CAR T cell therapies are the complex in vitro engineering procedures required to produce safe and robust in vivo anti-tumor T cell responses [135]. In these therapies, T cells are (1) isolated from patients, (2) propagated in ex vivo cultures, (3) engineered with vectors to express specific TCRs, (4) selected and expanded in culture, and finally (5) reinfused into the same patient (Fig. 3A). Each of these steps will require further investigation and optimization in order for ACT to be exploited for BCBM intervention. Nanomedicine, however, may allow us to negate some or all of these experimental manipulations (Fig. 3B, C). NPs have been used to manipulate adoptively transferred T cells, with earlier studies demonstrating that adjuvant-loaded NPs conjugated to T cell surface proteins can enhance T cell persistence and function in vivo upon reinfusion into patients [172, 173]. These NPs, termed T cell backpacks (Fig. 3B), can be used to provide exogenous T cell stimulation or to exploit T cell tumor-homing properties as means to deliver therapeutics to tumors [174].

TCRs cluster together in regions referred to as “immunological synapses,” which are required for effective T cell activation upon interaction with APCs [175]. In this vein, several NPs have been proposed for use as artificial APCs (aAPCs) for various purposes. Intricately designed, carbon nanotube-polymer composites (CNPs) have been engineered as aAPCs for optimal expansion of T cells isolated from mice (Fig. 3B) [176]. Carbon nanotubes (CNTs) are first functionalized with multivalent T cell antigens and costimulatory molecules (MHC-I and CD28), followed by CNT magnetite-mediated conjugation to PLGA NPs encapsulating IL-2: the former enables effective T cell stimulation while the latter provides paracrine IL-2 stimulation and the ability to magnetically separate CNPs from T cells following ex vivo expansion and prior to reinfusion. Crucially, adoptive transfer of these T cells back into melanoma-harboring mice resulted in delayed tumor growth, providing proof-of-concept for this approach in other solid tumors. In contrast to this study, NP backpacks need not be removed from T cells prior to reinfusion and can even be used to enable controlled drug delivery in vivo. For example, T cells can be engineered with NP backpacks that, upon reinfusion into patients, release human IL-15 super-agonist (IL-15Sa) in response to TCR stimulation, which allows for higher doses of IL-15Sa to be safely administered and improve efficacy in vivo [177].

Nanomedicine, however, is also making an impact in reducing the need to remove or manipulate patient T cells during ACT regimens in the first place (Fig. 3C). In a groundbreaking study, Smith et al. exploited the intrinsic properties of NPs to deliver leukemia-specific CAR genes to circulating T cells in vivo. Poly(lactic acid-co-glycolic acid)-block-PEG (PEG-block-poly (l-lactide) NPs were targeted to T cells via surface functionalization with anti-CD3e F(ab)2 fragment, the CD19 CAR gene construct was delivered to the nucleus with the aid of nuclear localization and microtubule-associated sequences, and the gene was introduced into DNA via a cut-and-paste mechanism mediated by piggyBac transposase elements flanking the CD19 construct. These NPs were not only capable of reprogramming T cells in situ and inducing efficacy comparable to that of conventional CAR T cell infusions, but they were also able to generate long-lived memory T cells that sustain CAR expression for weeks [178]. Such in vivo engineering and expansion of T cells with NPs reduce safety and efficacy complications associated with ex vivo procedures, and represent a promising new strategy to engineer T cells. Ongoing work has begun to clarify how various NPs can be optimized for gene delivery to human T cells [179].

A final nano-IT strategy targeting T cells involves targeted delivery of immunostimulatory materials. CTLA-4 siRNA has been successfully encapsulated in PEG-block-poly (lactide) NPs and able to reduce CTLA-4 expression in T cells in vitro [180]. PD-1 expression by T cells has also been targeted with NPs. In one such study, poly(lactic acid-co-glycolic acid)-block-poly (ethylene glycol) copolymers were designed to selectively target PD-1+ T cells through surface functionalization with CD8 and PD-1 antibodies (Table 3), which effectively targeted CD8+ T cells in the blood, lymphoid tissues, and melanoma tumors [181]. PD-1 antibody fragments serve dual purposes in this system: to target specific T cell subsets and to neutralize PD-1 receptors on T cells. Furthermore, these NPs were co-encapsulated with TLR7/8 agonists, enabling sustained release of these immunostimulants. Both of these studies were performed in
mouse models of melanoma; however, NP encapsulation of PD-L1 [182] and PD-1 siRNA [183] has also begun to be studied in primary BC models. For example, Wu et al. investigated use of two inorganic NPs—layered double hydroxide (LDH) and lipid-coated calcium phosphate (LCP) NPs—for PD-1 and PD-L1 siRNA delivery, demonstrating LCPs exhibit better cellular uptake and gene delivery. In contrast to polymeric NPs, lipid NPs typically utilize ionizable or cationic lipids, such as 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) used in these LCP NPs, which aids in endosomal escape and release of negatively charged material. Such characteristics, combined with use of cholesterol and PEG to improve NP stability, make lipid NPs a preferential delivery platform for nucleic acids [140]. Continued investigation into such strategies will inform on the utility of nano-ICIs in BCBMs, as these were performed in primary BC models.

**Targeting APCs and nanovaccines**

NPs can be engineered to capture released TAg’s following cytotoxic tumor cell death, and subsequently present the TAg’s to local APCs [103, 104]. This augments in situ anti-cancer vaccination and amplifies APC-mediated activation of TAg-reactive T cells. Such NPs, formulated using PLGA-based polymers and surface modifications that enable binding of tumor-derived proteins, have been shown to successfully present TAg’s to APCs and synergize with ICIs in mouse models of melanoma [184]. Such TAg-capturing NPs have been shown to improve IT while also improving the abscopal effect. The utility of such a strategy has yet to be explored for BCBMs; however, combining this strategy with existing BC DC vaccination trials (NCT02808416, NCT01782274, NCT03638765) warrants investigation.

**Utilizing myeloid cells as NP carriers**

Both macrophages and their circulating precursors, monocytes, have an intrinsic ability to take up microparticles and NPs, and similar to that of T cells, intrinsically home to areas of inflammation such as BCBMs. Together with an ability to penetrate the BBB, these properties enable the possibility that such myeloid cells may be utilized for NP delivery to tumors and represent an exciting new direction of the nanotech field. While these strategies first emerged in the context of T cell backpacks, myeloid cell carriers were first reported in Parkinson’s disease models [185] and have since been explored for NP delivery to tumors. Monocyte-derived macrophages were introduced as cellular NP carriers for drug delivery to the CNS due their ability to traffic to sites of tissue damage or inflammation [186]. Ullah et al. recently expanded upon this method and provided proof-of-principle for this targeted drug platform in 3D coculture and spheroid tumor models, exploiting an external alternating magnetic field (AMF) to induce heat locally and trigger temperature-dependent release of drugs from NPs [136]. The authors use macrophages as carriers for their silica-coated superparamagnetic iron oxide NPs (SPIONs), which upon application of the AMF, also simultaneously kills the macrophages. Thus, this drug delivery method induces dual targeting of tumor cells and infiltrating, NP-carrying TAMs. This strategy has also been studied in glioma [187] and other extracranial tumor models [188], as well as using other myeloid cell carriers such as neutrophils [189]. Work in primary tumor models, however, suggests that neutrophils do not take up NPs themselves, but instead transiently disrupt the tumor vasculature to allow for NP accumulation [190]. Cytotoxic CD8+ T cells are also being investigated as potential NP carriers to tumors in preclinical models, becoming backpacks for the NPs themselves [191]. Further studies are necessary to clarify this mechanism and see if this drug delivery method is efficacious in tumors that require BBB penetration.

**Targeting the immunogenic cell death response via nanotechnology**

A rapidly expanding strategy in nano-IT involves use of RT in combination with NP treatment in promotion of ICD. Though studied in immunocompromised mice, iodine NPs (INPs) were recently employed to increase absorption and local deposition of RT energy, which doubled the survival of mice with BCBMs compared to mice treated with RT alone [192]. Follow-up studies in immunocompetent mice will further indicate the translational potential of this strategy in humans. A more advanced example of this strategy is Activation and Guidance of Irradiation by X-ray (AGuIX), a new gadolinium-based NP in clinical trials as a radiosensitizer in BCBM patients in combination with WBRT. AGuIX has contrast-enhancing, cytotoxic, and RT-absorbing properties, the latter of which likely promotes ICD [193]. Additional approaches to combine RT and nanomedicine continue to emerge. Chen et al. recently used a CRISPR screen and identified that leucine-rich repeat-containing protein 31 (LRRC31) sensitizes BCBMs to radiation [194]. After revealing LRRC31’s role as a major DNA repair suppressor, the authors used 60% Hexadecanolide (HDL)-diethyl sebacate (DES)-N-methyldiethanolamine (MDEA) PEG polymers (HDL-DES-MDEA-PEG) conjugated to chlorotoxin, a brain tumor-targeting peptide, to encapsulate lexiscan for increased BBB permeability (Table 3). The authors then used these autocatalytic brain tumor-targeted NPs (ABTT NPs) to deliver LRCC31 cDNA, which increased the survival of BCBM-harboring mice following RT.
Hydrogel-based drug delivery systems for IT

A known limitation of systemically administered ITs involves the potential to offset immune homeostasis at off-target sites, thus increasing the risk of fatal side effects [195]. Hydrogel-based biomaterials have been explored in several reports for sustained, localized delivery of various therapeutic agents to tumors [196], providing a foundation to expand such technologies towards delivery of ITs for local immunomodulation. Of notable mention, an intracranially implanted liquid crystal polymer-based microcapsule drug depot has demonstrated the potential of hydrogel-like systems for localized BCBM drug delivery [197]. This non-biofouling implant enabled the codelivery of two clinical chemotherapeutics, temozolomide and doxorubicin, resulting in improved survival of mice with BCBMs [197]. Unlike non-degradable macroscale drug depots, hydrogels are composed of cross-linked polymeric matrices that form hydrated macro- to nano-scale three-dimensional structures [196, 198]. These biomaterials can be engineered for local and controlled release to improve therapeutic efficacy and limit systemic exposure [199]. For cancer IT, hydrogel-based drug delivery systems can also enhance the local efficiency of ICD-inducing therapies by increasing the local concentration and residence time of ICD-inducing drugs and NPs, and can be rendered thermosensitive for rapid in situ sol–gel transitions at physiological temperatures, which makes them useful for local deployment via injections [200].

Not surprisingly, various locally applied hydrogel-based drug delivery systems have shown excellent therapeutic potential for local TME immunomodulation in gliomas [201, 202], holding promise that this strategy may increase the delivery and efficacy of ITs for BCBMs. While investigations into hydrogels for BCBM IT delivery are just beginning to be reported, several groups have begun leveraging hydrogel technology to improve IT drug delivery in extracranial BC models. In primary 4T1 BC tumors, for example, thermal-sensitive Pluronic F-127 polymer-based hydrogels have been used to enhance the delivery and efficacy of liposomes containing Imiquimod, a TLR agonist, in tumor-bearing mice [203]. Similarly, alginate-based hydrogel systems have been used to co-deliver CpG to synergize with systemic ICI treatment, resulting in synergized anti-tumor activity in mice [204]. In this system, hydrogels were also loaded with radio-labeled catalase, enabling highly localized radiation, alleviation of tumoral hypoxia, and complete tumor regression in mice. In addition to TLR agonists, ICIs have also been incorporated into hydrogel delivery systems. Alginate polymer-based hydrogels have been used for dual delivery of two FDA-approved drugs—PD-1 mAb and the COX2 inhibitor celecoxib—in mice harboring 4T1 BC lung metastases [205]. This hydrogel-based system enabled local sustained release of the two drugs, resulting in high drug concentrations in the TME and peripheral circulation, a reduction of tumor burden, and significantly improved local and systemic anti-tumor immunity by mobilizing effector T cells and reducing Tregs and MDSCs in the TME.

Employment of hydrogels for IT delivery also has the potential to increase the immunogenicity of tumors. For example, hydrogel-based systems can be used to locally deliver encapsulated TAg’s, which can increase the efficacy of locally applied ITs. Tumor-derived TAg’s have been encapsulated with indocyanine green (ICG) and JQ1, a drug known to suppress PD-L1 expression, in injectable hydrogels containing the tumor penetrable peptide sequence Fmoc-KCRGDK. The cellular release of this molecular cargo upon near-infrared (NIR) illumination serves both as a vaccine node and as a reservoir for local ICI [206].

Hydrogel-based systems can also be used to improve T cell responses and therapies. For example, a nanocomposite system composed of macroporous alginate hydrogels modified with the collagen mimicking GFOGER peptide and loaded with silica microparticles that release IL-15–IL-15Rα complexes has been described. The GFOGER peptide aids cargo upon near-infrared (NIR) illumination serves both as a vaccine node and as a reservoir for local ICI [206].

Hydrogel-based systems can also be used to improve T cell responses and therapies. For example, a nanocomposite system composed of macroporous alginate hydrogels modified with the collagen mimicking GFOGER peptide and loaded with silica microparticles that release IL-15–IL-15Rα complexes has been described. The GFOGER peptide aids

Limitations of nanotech for immunotherapy

Despite the promise of nano-IT, there are several limitations that need to be addressed. For example, NPs are still subject to clearance mechanisms from the circulation. Phagocytes comprising the MPS take up NPs and promote clearance by the liver and spleen [140]. NPs can be designed for decreased interaction with the MPS, such as through PEGylation, but the MPS also reveals clearance as a major flaw to strategies seeking to use myeloid cells as NP carriers, as these phagocytes mediate clearance through these tissues. NP interactions with the MPS are also the source of another potential limitation of nanotherapeutics, as these phagocytes can trigger adverse immune responses. PEGylation has recently been shown to cause anaphylaxis in small numbers of patients, which may be mediated in part by anti-PEG antibodies [140]. Investigation into the nuances of the interaction between the MPS and any given NP formulation will
be important for its translational potential and negating the risk of adverse allergic reactions in clinical trials. Another confounding issue for targeted nanotherapeutics is the formation of protein coronas upon exposure to serum proteins in the systemic circulation, which can interfere with NP targeting. Though the mechanisms regulating NP interactions with serum proteins are just beginning to be understood, strategies such as cloaking NPs with protein corona shields are under investigation [208]. A final lingering barrier to the translational potential of nano-IT involves scale-up difficulties. NP production strategies utilizing bottom-up processes will need to be scaled up by pharmaceutical companies that predominantly rely on top-down methods [209]. Therefore, maintaining the desired NP formulation characteristics will be especially important for translating nano-IT.

**Conclusions and future directions**

The introduction of IT has revolutionized cancer treatments, and despite the exclusion of most BM patients from many early clinical trials, there is expanding and compelling evidence that ITs provide a therapeutic benefit to BCBM patients. As discussed here, these IT strategies remain subject to several crucial barriers for BCBM efficacy including poor BBB permeability, significant safety uncertainties, drug resistance, and an inability to overcome immunosuppressive thresholds to mount an anti-tumor response. Nanomedicine, which has greatly improved intracranial drug delivery and tumor targeting of BCBMs, is particularly poised to overcome these barriers to IT utility. NPs afford the ability to control drug release, which can substantially reduce side effects of a given drug while simultaneously increasing its safety profile. Additionally, fine-tuning of NP physicochemical properties enables targeting of NPs to specific tissues or cell types, further reducing risk of non-specific toxicities. Nanomedicine may therefore have the capability to release the full potential of ITs for BCs in general, but particularly once it has spread to the brain.

As more progress is made in understanding the BCBM tumor-immune microenvironment, new opportunities for IT and nanomedicine are likely to emerge. NPs targeting other immune cell types will likely appear in future BCBM studies. For example, MDSC depletion via polymer NPs loaded with 6-thioguanine has been studied in the context of melanoma [210]. The communication between immune populations and metastatic BC cells is just beginning to be explored; likewise, the interaction of NPs with immune populations is just beginning to be understood. Filling these gaps will greatly improve ITs, nanotherapies, and nano-IT. Still, progress in the field will depend on inclusion of BCBM patients in future clinical trials, as several previously ongoing IT clinical trials have been terminated as a result of low accrual (NCT02669914, NCT00227656, NCT01132664). As the field of nanotechnology expands, potentially leading to the identification of new classes of NP carriers harboring endogenous anti-tumor activity, new directions for BCBM IT will emerge.

**Funding** NIH R37 CA218617 (PI: A Kim), NIH RO1 NS108813 (PI: G Woodworth). TEDCO Maryland Innovation Initiative (MII) Commercialization Program: Technology Assessment Phase (Co-PIs: A Kim, G Woodworth, J Winkles).

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer. 1996;78:1781–8.
2. Sammons S, Van Swearingen AED, Anders CK. The promise of immunotherapy for breast cancer brain metastases. Curr Breast Cancer Rep. 2019;11:241–7.
3. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol. 2005;75:5–14.
4. Rostami R, Mittal S, Rostami P, Tavassoli F, Jabbari B. Brain metastasis in breast cancer: a comprehensive literature review. J Neurooncol. 2016;127:407–14.
5. Witzel I, Oliveira-Ferrer L, Pantel K, Muller V, Wikman H. Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res. 2016;18:8.
6. Mounsey LA, Deal AM, Keith KC, Benbow JM, Shachar SS, Zagar T, Dees EC, Carey LA, Ewend MG, Anders CK. Changing natural history of HER2-positive breast cancer metastatic to the brain in the era of new targeted therapies. Clin Breast Cancer. 2018;18:29–37.
7. Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQ. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol. 2017;19:i1–24.
8. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol. 2018;20:i1–86.
9. McConnell HL, Kersch CN, Woltjer RL, Neuwell EA. The translational significance of the neurovascular unit. J Biol Chem. 2017;292:762–70.
10. Wingrove E, Liu ZZ, Patel KD, Arnal-Estape A, Cai WL, Melnick MA, Politi K, Monteiro C, Zhu L, Valiente M, Kluger HM, Chiang VL, Nguyen DX. Transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasis. Cell Rep. 2019;27:1277–1292 e1277.
11. Muldoon LL, Alvarez JI, Begley DJ, Boado RJ, Del Zoppo GJ, Doolittle ND, Engelhardt B, Hallenberg JM, Lonser RR, Ohl fest JR, Prat A, Scarpa M, Smeyne RJ, Drewes LR, Neuwell EA. Immunologic privilege in the central nervous system and the blood–brain barrier. J Cereb Blood Flow Metab. 2013;33:13–21.

12. Fitzgerald DP, Palmieri D, Hua E, Hargrave E, Herring JM, Qian Y, Vega-Valle E, Weil RJ, Stark AM, Vortmeyer AO, Steeg PS. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis. 2008;25:799–810.

13. Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res. 2018;24:511–20.

14. Galea I, Bechmann I, Perry VH. What is immune privilege (not)? Trends Immunol. 2007;28:12–8.

15. Ransohoff RM, Kvisiask P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol. 2003;3:569–81.

16. Lorger M, Felding-Habermann B. Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am J Pathol. 2010;176:2958–71.

17. Sleeman JP. The metastatic niche and stromal progression. Cancer Metastasis Rev. 2012;31:429–40.

18. Lynn SJ, Green JP, Accardi M, Cleere C. Hypnosis and smoking cessation: the state of the science. Am J Clin Hypn. 2010;52:177–81.

19. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol. 2011;21:139–46.

20. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Doolittle ND, Engelhardt B, Hallenbeck JM, Lonser RR, Ohlfest JR, Prat A, Scarpa M, Smeyne RJ, Drewes LR, Neuwell EA. Immunologic privilege in the central nervous system and the blood–brain barrier. J Cereb Blood Flow Metab. 2013;33:13–21.

21. Carbonell WS, Ansong O, Sibson N, Muschel R. The vascular basement membrane as “soil” in brain metastasis. PLoS ONE. 2009;4:e5857.

22. Wagenblast E, Soto M, Gutierrez-Angel S, Hartl CA, Gable AL, Maceli AR, Erard N, Williams AM, Kim SY, Dickopf S, Harrell JC, Smith AD, Perou CM, Wilkinson JE, Hannon GJ, Knott SR. A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature. 2015;520:358–62.

23. Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond. Cancer Metastasis Rev. 2006;25:521–9.

24. Fares J, Fares MY, Khachfe HH, Salah HB, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5:58.

25. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamber n B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Campion LR, Gatter KC, Diaspro A, Loda M, Zupi G, Biroccio A. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell. 2006;21:509–19.

29. Neman J, Termini J, Wilczynski S, Vaidhe N, Choy C, Kowolik CM, Li H, Hambrecht AC, Roberts E, Jandial R. Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc Natl Acad Sci USA. 2014;111:984–9.

30. Schnepf PM, Lee DD, Guldner IH, O’Tighearnaigh TK, Howe EN, Palakurthi B, Eckert KE, Toni TA, Ashfeld BL, Zhang S. GAD1 upregulation programs aggressive features of cancer cell metabolism in the brain metastatic microenvironment. Cancer Res. 2017;77:2844–56.

31. Sevenich L, Bowman RL, Mason SD, Quail DF, Rapaport F, Elie BT, Brogi E, Brastianos PK, Hahn WC, Holsinger LJ, Massague J, Leslie CS, Joyce JA. Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol. 2014;16:876–88.

32. Ren D, Zhu X, Kong R, Zhao Z, Sheng J, Wang J, Xu X, Liu J, Cui K, Zhang XH, Zhao H, Wong STC. Targeting brain-adaptive cancer stem cells prohibits brain metastatic colonization of triple-negative breast cancer. Cancer Res. 2018;78:2052–64.

33. Chen Q, Boire A, Jin X, Valiente M, Er EE, Lopez-Soto A, Jacob L, Patwa R, Shah H, Xu K, Cross JR, Massague J. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature. 2016;533:493–8.

34. Seano G, Nia HT, Embem KE, Das M, Ren J, Krishnan S, Kloepper J, Pinho MC, Ho WW, Ghosh M, Askoxylakis V, Ferraro GB, Kriedemann L, Gerstner ER, Batchelor TT, Wen PY, Lin NU, Grodzinsky AJ, Fukumura D, Huang P, Baisch JW, Padera TP, Munn LL, Jain RK. Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium. Nat Biomed Eng. 2019;3:230–45.

35. Greenhalgh AD, David S, Bennett FC. Immune cell regulation of glia during CNS injury and disease. Nat Rev Neurosci. 2020;21:139–52.

36. Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ, Chaft JE, Kris MG, Huse JT, Brogi E, Massague J. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 2014;156:1002–16.

37. Xing F, Liu Y, Sharma S, Wu K, Chan MD, Lo HW, Carpenter RL, Metheny-Barlow LJ, Zhou X, Qasem SA, Pasche B, Watabe K. Activation of the c-Met pathway mobilizes an inflammatory network in the brain microenvironment to promote brain metastasis of breast cancer. Cancer Res. 2016;76:4970–80.

38. Lin Q, Balasubramanian K, Fan D, Kim SY, Guo L, Wang H, Bar-Eli M, Aldepe KD, Fidler IJ. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia. 2010;12:748–54.

39. Ridler C. New drug blocks brain metastasis. Nat Rev Neurol. 2018;14:452.

40. Bowman RL, Klemm F, Akkari L, Pyonteck SM, Sevenich L, Quail DF, Dhara S, Simpson K, Gardner EE, Iacobuzio-Donahue CA, Brennan CW, Tabar V, Gutin PH, Joyce JA. Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Rep. 2016;17:2445–59.

41. Gomez Perdiguero E, Klapproth K, Schulz C, Busch K, Azzoni L, Crozet L, Garner H, Trouillet C, de Bruijn MF, Geissmann F, Hofmann C, Schulte-Hermann J, Ritter W, Wolf W, Wobick R, Walters F, Cardenas-Perez E, Crozet JE, Kris MG, Huse JT, Brogi E, Massague J. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 2014;156:1002–16.

42. Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res. 2018;24:511–20.
43. Chen Q, Zhang XH, Massague J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell. 2011;20:538–49.

44. Rippa N, Taggart D, Williams J, Andreou T, Wurdek H, Wroneki K, Lorger M. Metastatic site-specific polarization of macrophages in intracranial breast cancer metastases. Oncotarget. 2016;7:41473–87.

45. Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31:326–41.

46. He BP, Wang JJ, Zhang X, Wu Y, Wang M, Bay BH, Chang AY. Differential reactions of microglia to brain metastasis of lung cancer. Mol Med. 2006;12:161–70.

47. Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. 2016;19:20–7.

48. Pukrop T, Dehghan F, Chuang HN, Lohaus R, Bayanga K, Heermann S, Regen T, Van Rossum D, Klemm F, Schulz M, Siam L, Hoffmann A, Trumpf L, Stadelmann C, Bechmann I, Hanisch UK, Binder C. Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way. Glia. 2010;58:1477–89.

49. Wu SY, Xing F, Sharma S, Wu K, Tyagi A, Liu Y, Zhao D, Deshpande RP, Shiozawa Y, Ahmed T, Zhang W, Chan M, Ruiz J, Lycan TW, Dothard A, Watabe K. Nicotine promotes brain metastasis by polarizing microglia and suppressing innate immune function. J Exp Med. 2020;217:e20191131.

50. Chuang HN, van Rossum D, Sieger D, Siam L, Klemm F, Bleckberger T, Bauerlova M, Farhat K, Scheffel J, Schulz M, Dehghan F, Stadelmann C, Hanisch UK, Binder C, Pukrop T. Carcinoma cells misuse the host tissue damage response to invade the brain. Glia. 2013;61:1331–46.

51. Xing F, Liu Y, Wu SY, Wu K, Sharma S, Mo YY, Feng J, Sanders S, Jin G, Singh R, Vidi PA, Tyagi A, Chan MD, Ruiz J, Debinski W, Pasche BC, Lo HW, Metheny-Barlow LJ, D’Agostino RB Jr, Watabe K. Loss of XIST in breast cancer activates MSN-c-Met signaling and reprograms microglia via exosomal miRNA to promote brain metastasis. Cancer Res. 2018;78:4316–30.

52. Berghoff AS, Fuchs E, Rickers G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H, Zielinski C, Bartlisch R, Birner P, Galon J, Preusser M. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology. 2016;5:e1057388.

53. Duchnowska R, Peksa R, Radecka B, Mandat T, Trojanowski J, Tarosz B, Czartoryska-Arlukowicz B, Olszewski WP, Och W, Kalinka-Warzocha E, Kozlowski W, Kowalczyk A, Loi S, Biernat W, Jassem J, Polish Brain Metastasis C (2016) Immune rejection: immunologic trends in brain metastasis. Oncoimmunology. 2016;5:e1172153.

54. Sugihara AQ, Rolle CE, Lesniak MS. Regulatory T cells actively infiltrate metastatic brain tumors. Int J Oncol. 2009;34:1533–40.

55. Liu Y, Kosaka A, Ikura M, Kohanbash G, Fellows-Mayle W, Snyder LA, Okada H. Premetastatic soil and prevention of breast cancer brain metastasis. Neuro Oncol. 2013;15:891–903.

56. Chan IS, Knutsdottir H, Ramakrishnan G, Padmanaban V, Warriner M, Ramirez JC, Dunworth M, Zhang H, Jaffee EM, Bader JS, Ewald AJ. Cancer cells educate natural killer cells to a metastasis-promoting cell state. J Cell Biol. 2020. https://doi.org/10.1083/jcb.202001134.

57. Harary M, Reardon DA, Iorgulescu JB. Efficacy and safety of immune checkpoint blockade for brain metastases. CNS Oncol. 2019;8:CNS33.

58. Vitkovic L, Maeda S, Sternberg E. Anti-inflammatory cytokines: expression and action in the brain. Neuroimmunomodulation. 2001;9:295–312.

59. Saha D, Martuzza RL, Rabkin SD. Macrophage polarization contributes to glioblastoma eradication by combination immunonirotherapy and immune checkpoint blockade. Cancer Cell. 2017;32:253-267 e255.

60. Lanier CM, Hughes R, Ahmed T, LeCompte M, Masters AH, Petty WJ, Ruiz J, Triozzi P, Su J, O’Neill S, Watabe K, Cramer CK, Laxton AW, Tatter SB, Wang G, Whitlow C, Chan MD. Immuno­therapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries. Neurooncol Pract. 2019;6:402–9.

61. Tasbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379:722–30.

62. Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA. Combination nivolumab and ipilimumab or
nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2a trial. Lancet Oncol. 2018;19:672–81.
75. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JJ, Sznel M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13:459–65.
76. Iorgulescu JB, Harary M, Zogg CK, Ligon KL, Reardon DA, Hodi FS, Aizer AA, Smith TR. Improved risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: results from a national cohort. Cancer Immunol Res. 2018;6:1039–45.
77. McArthur H, Beauchamp KM, Halpenny D, Henrich M, Modi S, Patil S, Young R, Kaley T, Merghoub T, Barker C, Wong P, Hamilton N, Hudis C, Wolchok J, Norton L. Abstract 4705: CTLA4 blockade with HER2-directed therapy (H) yields clinical benefit in women undergoing radiation therapy (RT) for HER2-positive (HER2+) breast cancer brain metastases (BCBM). Cancer Res. 2017;77:4705.
78. Brustianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cubillas K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG 2nd, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway LA, Gabriel S, Lander ES, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC. Genomic characterization of breast metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015;5:1164–77.
79. Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, Livasy C, Frichtie K, Prat A, Harrell JC, Ewend MG, Carey LA, Miller CR, Anders CK. Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Res. 2011;13:R125.
80. Blazquez R, Wlochowitz D, Wolf S, Seitz S, Wachtler A, Perera-Bel J, Bleckmann A, Beissbarth T, Salinas G, Riemenschneider M, Proescholdt M, Evert M, Utpatel K, Siam L, Schatlo B, Bel J, Bleckmann A, Ben-Eliyahu S, Blinder P. Prophylactic TLR9 stimulation diminishes alpha-beta and gamma-delta T cells and reduces the tumour microenvironment. Cancer Immunol Res. 2015;3:65–79.
81. Pukrop T. Anti-CSF-1R treatment is effective to prevent carcinogenic invasion induced by monocytic-derived cells but scarcely by microglia. Oncotarget. 2015;6(17):15482–93.
82. Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, Pynnonen S, Daniel D. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 (+) T cells. Oncoimmunology. 2013;2:e26968.
83. Ni J, Ramkissoon SH, Xie S, Geol S, Stover DG, Guo H, Loo V, Marco E, Ramkissoon LA, Kang YJ, Hayashi M, Nguyen QD, Ligon AH, Du R, Claus EB, Alexander BM, Yuan GC, Wang ZC, Iglesiat JD, Krop IE, Roberts TM, Winer EP, Lin NU, Ligon KL, Zhao JJ. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016;22:723–6.
84. Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol. 2014. https://doi.org/10.1101/cshperspect.a021857.
85. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstrom K, West BL, Coussens LM. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2015;11:54–67.
86. Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echeverria C, Yang WK. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther. 2009;8:2204–10.
87. Wen PY, Omuoro A, Ahiuwaus MS, Fathallah-Shaykh HM, Mohile N, Laird JJ, Laird AD, Tang J, Jiang J, Egile C, Cloughesy TF. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro Oncol. 2015;17:1275–83.
88. Niu J, Ramkissoon SH, Xie S, Geol S, Stover DG, Guo H, Loo V, Marco E, Ramkissoon LA, Kang YJ, Hayashi M, Nguyen QD, Ligon AH, Du R, Clauss EB, Alexander BM, Yuan GC, Wang ZC, Iglesiat JD, Krop IE, Roberts TM, Winer EP, Lin NU, Ligon KL, Zhao JJ. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Br Cancer Res. 2017;77:4705.
89. Brustianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cubillas K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG 2nd, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway LA, Gabriel S, Lander ES, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC. Genomic characterization of breast metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015;5:1164–77.
90. Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, Livasy C, Frichtie K, Prat A, Harrell JC, Ewend MG, Carey LA, Miller CR, Anders CK. Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Res. 2011;13:R125.
91. Blazquez R, Wlochowitz D, Wolf S, Seitz S, Wachtler A, Perera-Bel J, Bleckmann A, Beissbarth T, Salinas G, Riemenschneider M, Proescholdt M, Evert M, Utpatel K, Siam L, Schatlo B, Bel J, Bleckmann A, Ben-Eliyahu S, Blinder P. Prophylactic TLR9 stimulation diminishes alpha-beta and gamma-delta T cells and reduces the tumour microenvironment. Cancer Immunol Res. 2015;3:65–79.
92. Purop T, Klemm F, Hagemann T, Gradl D, Schulz M, Siemes S, Trumper L, Binder C, Wot Sa signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proc Natl Acad Sci USA. 2006;103:5454–9.
93. Krieg AM. Therapeutic potential of Toll-like receptor 9 activator. Nat Rev Drug Discov. 2006;5:471–84.
94. Goldfarb Y, Benish M, Rosene E, Melamed R, Levi B, Glasner A, Ben-Eliyah Y. CpG-C oligodeoxynucleotides limit the deleterious effects of beta-adrenoceptor stimulation on NK cytotoxicity and metastatic dissemination. J Immunol. 2009;132:280–91.
95. Benbenisty A, Gadrich M, Cottarelli A, Lubarti A, Kain D, Amer M, Shaashua L, Glasner A, Erez N, Agullius D, Mayo L, Ben-Eliyah Y, Blinder P. Prophylactic TLR9 stimulation reduces brain metastasis through microglia activation. PLoS Biol. 2019;17:e2006859.
96. Phan GQ, Rosenberg SA. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Control. 2013;20:289–97.
97. Hong JJ, Rosenberg SA, Dudley ME, Yang JC, White DE, Butman JA, Sherry RM. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res. 2010;16:4892–8.
98. Grubert RC, Couchs LP, Smith JA, Olson S, Gall J, Young WB, Davol PA, Lum LG. Human T cells armed with Her2/neu...
bispacific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res. 2006;12:569–76.

101. Lum LG, Thakur A, Al-Kadhimi Z, Colvin GA, Cummings FJ, Legare RD, Dizon DS, Kouttab N, Maizel A, Colaiace W, Liu Q, Rathore R. Targeted T-cell therapy in stage IV breast cancer: a phase I clinical trial. Clin Cancer Res. 2015;21:2305–14.

102. Priceman SJ, Tilakawardane D, Jeang B, Brandt K, Wahle C, Bernhard H, Knuth A, Jager E. Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates. Cancer Immunol Res. 2014;2:404–9.

103. Sears AK, Perez SA, Clifton GT, Gates JD, Clive KS, Holmes JP, Lum LG, Shumway NM, Van Echo DC, Carmichael MG, Bennion TA. Plasma levels of dendritic cells and their role in immunotherapy in glioblastoma: from preclinical studies to clinical trials. Cancers (Basel). 2019;11:537.

104. Karbach J, Gnijat S, Biskamp M, Atmaca A, Weidmann E, Brandt K, Wahle C, Bernhard H, Knuth A, Jager E. Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates. Cancer Immunol Res. 2014;2:404–9.

105. Sears AK, Perez SA, Clifton GT, Benavides LC, Gates JD, Clive KS, Holmes JP, Lum LG, Shumway NM, Van Echo DC, Carmichael MG, Bennion TA. Plasma levels of dendritic cells and their role in immunotherapy in glioblastoma: from preclinical studies to clinical trials. Cancers (Basel). 2019;11:537.

106. Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Baxevanis CN, Mintendorf EA, Papamichail M, Peoples GE. AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opin Biol Ther. 2011;11:1543–50.

107. Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Peoples GE. Final report of the phase II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014;25:1735–42.

108. Brown JS, Sundar R, Lopez J. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. Br J Cancer. 2014;110:312–24.

109. Yum S, Li M, Chen ZJ. Old dogs, new trick: classic cancer therapeutics activate cGAS. Cell Res. 2020;30:639–48.

110. Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Narita Y, Shibui S, Fujiiwara Y. Disruption of the blood-brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer. 2010;116:302–8.

111. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22:3608–17.

112. Yokota K, Fine RL. Increased permeability of the blood–brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol. 2007;25:2306–12.

113. Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CL. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol. 2013;24:1526–33.

114. Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticle conjugates for drug delivery to the central nervous system. Adv Drug Deliv Rev. 2012;64:701–5.

115. Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorshois RR. Radiosurgery for melanoma patients with brain metastases and impairment of blood–brain barrier. J Neurooncol. 2015;118:312–24.

116. Karbach J, Gnijat S, Biskamp M, Atmaca A, Weidmann E, Brandt K, Wahle C, Bernhard H, Knuth A, Jager E. Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates. Cancer Immunol Res. 2014;2:404–9.

117. Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Narita Y, Shibui S, Fujiiwara Y. Disruption of the blood-brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer. 2010;116:302–8.

118. Bachelot T, Romieu G, Campone M, Diers V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Goncalves A, Lehermeur M, Domont J. Guttierrez M, Cure H, Herrero JM, Labbe-Divilliers C. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14:64–71.

119. Kalsi R, Feigenberg S, Kwok Y, Tkaczuk K, Mehta M, Chun -sri S. Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. Clin Breast Cancer. 2015;15:e163–66.

120. Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, Miles D, Samant M, Welslau M, Dieras V. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26:113–9.

121. Warren KE. Beyond the blood-brain barrier: the importance of central nervous system (CNS) pharmacokinetics for the treatment of CNS tumors, including diffuse intrinsic pontine glioma. Front Oncol. 2018;8:239.

122. Arvanitis CD, Ferraro GB, Jain RK. The blood–brain barrier and brain-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20:26–41.

123. Kabraj S, Ni J, Lin NU, Xie S, Winer EP, Zhao JJ. Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain? Clin Cancer Res. 2018;24:1795–804.

124. Venur VA, Leone JP. Targeted therapies for brain metastases responding to primary systemic therapy with T-DM1. J Neurooncol. 2014;116:205–6.

125. Williams N, Wuthrick E, Kim H, Palmer J, Garg S, Eldredge-Hindy H, Daskalakis C, Feeney K, Mastrangelo M, Kim L, Sato T, Olencki T, Liebner D, Farrell C, Evans J, Judy K, Andrews D, Dicker A, Werner-Wasik M, Shi W, Kendra K. Phase I study of ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases. JHN J. 2018. https://doi.org/10.29046/JHNJ.013.1.003.

126. Stemmler HJ, Schmidt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier. Anticancer Drugs. 2007;18:23–8.

127. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22:3608–17.

128. Yokota K, Fine RL. Increased permeability of the blood–brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol. 2007;25:2306–12.

129. Bachelot T, Romieu G, Campone M, Diers V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Goncalves A, Lehermeur M, Domont J. Guttierrez M, Cure H, Herrero JM, Labbe-Divilliers C. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14:64–71.

130. Karbach J, Gnijat S, Biskamp M, Atmaca A, Weidmann E, Brandt K, Wahle C, Bernhard H, Knuth A, Jager E. Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates. Cancer Immunol Res. 2014;2:404–9.
131. Sznol M, Postow MA, Davies MJ, Pavlick AC, Pлимак ER, Shaheen M, Veloski C, Robert C. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017;58:70–6.

132. Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebbe C, Kirkwood JM, Schachter J, Daniels GA, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, McCaffrey J, Power D, Walker D, Bhore R, Jiang J, Hodi FS, Wolchok JD. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol. 2017;35:3815–22.

133. Albarel F, Gaudy C, Castinetti F, Carre T, Morange I, Contedevolx B, Grob J, Brue T. Long-term follow-up of plasmidum-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;172:195–204.

134. Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang Sherry RM, Klebaniow CA, Kammla US, Sherr PM, Perez A, Yuan CM, Feldman T, Friedman JW, Roschewski MJ, Feldman SA, McIntyre L, Toomey MA, Rosenberg SA. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35:1803–13.

135. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321–30.

136. Ullah S, Seidel K, Turkkan S, Warwas DP, Dubich T, Rohde M, Brudno JN, Kochenderfer JN. Toxicities of chimeric anti-CD19 chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321–30.

137. Matsumura Y, Maeda H. A new concept for macromolecular drug targeting: the enhanced permeability and retention effect and its applications to tumor chemo- and gene therapy. Adv Drug Deliv Rev. 2016;99:28–51.

138. Olive KJ Jr, Nielsen UB, Niyikiza C, Agresta SV, Wickham TJ. Targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol Appl Pharmacol. 2012;262:1–10.

139. Espelin CW, Leonard SC, Geretti E, Wickham TJ, Hendriks BS. Dual HER2 targeting with trastuzumab and liposomal-encapsulated doxorubicin (MM-302) demonstrates synergistic antitumor activity in breast and gastric cancer. Cancer Res. 2016;76:1517–27.

140. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020. https://doi.org/10.1038/s41552-019-0165-2.

141. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28–51.

142. Shah N, Mohammad AS, Saralkar P, Sprouls WA, Vickers SD, John D, Tallman RM, Luecke-Wold BP, Jarrell KE, Pinti M, Nolan RL, Lockman PR. Investigational chemotheraphy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. Pharmacol Res. 2018;132:47–68.

143. Uchida Y, Ohtsuki Y, Ikeda C, Suzuki T, Kamiie J, Terasaki T. Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors. J Neurochem. 2011;117:333–45.

144. Wyatt EA, Davis ME. Method of establishing breast cancer brain metastases affects brain uptake and efficacy of targeted, tethered nanoparticles. Bioeng Transl Med. 2019;4:30–7.

145. Wyatt EA, Davis ME. Nanoparticles containing a combination of a drug and an antibody for the treatment of breast cancer brain metastases. Mol Pharm. 2020;17:717–21.

146. Wiley DT, Webster P, Gale A, Davis ME. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci USA. 2013;110:8662–7.

147. Paris-Robidas S, Emond V, Tremblay C, Soulet D, Calon F. In vivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor. Mol Pharmacol. 2011;80:32–9.

148. Hamilton AM, Aaidoudi-Ahmed S, Sharma S, Kotamrajur VR, Foster PJ, Sugahara KN, Ruoslahti E, Rutt BK. Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain. J Mol Med (Berl). 2015;93:991–1001.

149. Ni J, Miao T, Su M, Khan NU, Ju X, Chen H, Liu F, Han L. PSMA-targeted nanoparticles for specific penetration of blood-brain tumor barrier and combined therapy of breast metastases. J Control Release. 2020;329:934–47.

150. Zhang S, Deng G, Liu F, Peng B, Bao Y, Du F, Chen AT, Liu J, Chen Z, Ma J, Tang X, Chen Q, Zhou J. Autocatalytic delivery of brain tumor-targeting, size-shrinkable nanoparticles for treatment of breast cancer brain metastases. Adv Funct Mater. 2020. https://doi.org/10.1002/adfm.201910651.

151. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97–111.

152. Reynolds JG, Geretti E, Hendriks BS, Lee H, Leonard SC, Klinzig NS, Noble CO, Lucke PB, Zandstra PW, Drummond DC, Oliver KJ Jr, Nielsen UB, Niyikiza C, Agresta SV, Wickham TJ. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol Appl Pharmacol. 2012;262:1–10.

153. Lee H, Shields AF, Siegel BA, Miller KD, Krop IE, Tripathy D, Verma S, Riahi K, Reynolds JG, Wickham TJ, Molnar I, Yardley DA. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naive, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer. 2016;16:352.

154. Lee H, Shields A, Siegel BA, Miller KD, Krop IE, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Nielsen UB, Wickham TJ, Hendriks BS. (64)Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer. Clin Cancer Res. 2017;23:4190–202.

155. Zhou Y, Zhang S, Chen Z, Bao Y, Chen AT, Shu WC, Liu F, Jiang Z, Zhou J. Targeted delivery of secretory promelittin via novel poly(lactone-co-beta-amino ester) nanoparticles for treatment of breast cancer brain metastases. Adv Sci (Weinh). 2020;7:1901866.
158. Wan X, Zheng X, Pang X, Pang Z, Zhao J, Zhang Z, Jiang T, Xu W, Zhang Q, Jiang X. Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain. Oncotarget. 2016;7:34038–51.

159. Bao Y, Zhang S, Chen Z, Chen AT, Ma J, Deng G, Xu W, Zhou J, Yu ZQ, Yao G, Chen J. Synergistic chemotherapy for breast cancer and breast cancer brain metastases via paclitaxel-loaded oleanolic acid nanoparticles. Mol Pharm. 2020;17:1343–51.

160. Dancy JG, Wadajkar AS, Connolly NP, Galstean R, Aimes HM, Peng S, Tran NL, Goloubeva OG, Woodworth GF, Winkles JA, Kim AJ. Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer. Sci Adv. 2020;6:eaax3931.

161. Dancy JG, Wadajkar AS, Schneider CS, Mauban JRH, Goloubeva OG, Woodworth GF, Winkles JA, Kim AJ. Non-specific binding and steric hindrance thresholds for penetration of particulate drug carriers within tumor tissue. J Control Release. 2016;238:139–48.

162. Wadajkar AS, Dancy JG, Roberts NB, Connolly NP, Strickland DK, Winkles JA, Woodworth GF, Kim AJ. Decreased non-specific adhesivity, receptor targeted (DART) nanoparticles exhibit improved dispersion, cellular uptake, and tumor retention in invasive gliomas. J Control Release. 2017;267:144–53.

163. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008;7:411–25.

164. Gustafson HH, Holt-Casper D, Grainger DW, Ghandehari H. Nanoparticle delivery of immunostimulants. Biomaterials. 2012;33:5776–87.

165. Buss CG, Bhatia SN. Nanoparticle delivery of immunostimulants. Nanomedicine (Lond). 2010;5:379–96.

166. Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw RB, Zheng Y, Maiarana J, Freeman GJ, Wucherpfennig KW, Irvine DJ. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol. 2018;36:708–16.

167. Pang L, Zhang C, Qin J, Han L, Li R, Hong C, He H, Wang J. A novel strategy to achieve effective drug delivery: exploit cells as carrier combined with nanoparticles. Drug Deliv. 2017;24:83–91.

168. Koch PD, Rodell CB, Kohler RH, Pittet MJ, Weissleder R. Myeloid cell-targeted nanocarriers efficiently inhibit cellular inhibitor of apoptosis for cancer immunotherapy. Cell Chem Biol. 2020;27:94–104105.

169. Chu D, Gao J, Wang Z. Neutrophil-mediated delivery of therapeutic nanoparticles across blood vessel barrier for treatment of inflammation and infection. ACS Nano. 2015;9:11800–11.
190. Naumenko VA, Vlasova KY, Garanina AS, Melnikov PA, Potashnikova DM, Vishnevskiy DA, Vodopyanov SS, Chekhonin VP, Abakumov MA, Majouga AG. Extravasating neutrophils open vascular barrier and improve liposomes delivery to tumors. ACS Nano. 2019;13:12599–612.

191. Wayteck L, Dewitte H, De Backer L, Breckpot K, De Smedt SC, Raemdonck K. Hitchhiking nanoparticles: reversible coupling of lipid-based nanoparticles to cytotoxic T lymphocytes. Biomaterials. 2016;77:243–54.

192. Hainfeld JF, Ridwan SM, Stanishevskiy FY, Smilowitz HM. Iodine nanoparticle radiotherapy of human breast cancer growing in the brains of athymic mice. Sci Rep. 2020;10:15627.

193. Verry C, Sancey L, Dufort S, Le Duc G, Mendoza C, Lux F, Grand S, Arnaud I, Quesada JL, Villen J, Tillement O, Balosso J. Treatment of multiple brain metastases using gadolinium nanoparticles and radiotherapy: NANO-RAD, a phase I study protocol. BMJ Open. 2019;9:e023591.

194. Chen Y, Jiang T, Zhang H, Gou X, Han C, Wang J, Chen AT, Ma J, Liu J, Chen Z, Jing X, Lei H, Wang Z, Bao Y, Baqri M, Zhu Y, Bindra RS, Hansen JE, Dou J, Huang C, Zhou J. LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy. Nat Cell Biol. 2020;22:1276–85.

195. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. The Lancet (London, England). 2018;391:933.

196. Knipe JM, Peppas NA. Multi-responsive hydrogels for drug delivery and tissue engineering applications. Regen Biomater. 2014;1:57–65.

197. Upadhyay UM, Tyler B, Pattnaik Y, Wicks R, Spencer K, Scott A, Masi B, Hwang L, Grossman R, Cima M, Brem H, Langer R. Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain. Proc Natl Acad Sci USA. 2014;111:16071–6.

198. Basso J, Miranda A, Nunes S, Cova T, Sousa J, Vitorino C, Pais A. Hydrogel-based drug delivery nanosystems for the treatment of brain tumors. Gels. 2018;4:62.

199. Singh A, Peppas NA. Hydrogels and scaffolds for immunomodulation. Adv Mater. 2014;26:6530–41.

200. Zhu J, Marchant RE. Design properties of hydrogel tissue-engineering scaffolds. Expert Rev Med Devices. 2011;8:607–26.

201. Wang F, Xu D, Su H, Zhang W, Sun X, Monroe MK, Chakrour RW, Wang Z, Dai W, Oh R, Wang H, Fan Q, Wan F, Cui H. Supramolecular produg hydrogelator as an immune booster for checkpoint blocker-based immunotherapy. Sci Adv. 2020;6:eaaaz8985.

202. Pan Z, Chen C, Li A, Jing W, Sun P, Huang X, Liu Y, Zhang S, Du W, Zhang R, Liu Y, Gong A, Wu J, Jiang X. Immunosuppressive hydrogel for the inhibition of malignant glioma relapse post-resection. Nat Nanotechnol. 2021;16:538–48.

203. Huang HJ, Tsai YL, Lin SH, Hsu SH. Smart polymers for cell therapy and precision medicine. J Biomed Sci. 2019;26:73.

204. Chao Y, Xu L, Liang C, Feng L, Xu J, Dong Z, Tian L, Yi X, Yang K, Liu Z. Combined local immunostimulatory radioisotope therapy and systemic immune checkpoint blockade impairs potent antitumor responses. Nat Biomed Eng. 2018;2:611–21.

205. Li Y, Fang M, Zhang J, Wang J, Song Y, Shi J, Li W, Wu G, Ren J, Wang Z, Zou W, Wang L. Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. Oncoimmunology. 2016;5: e1074374.

206. Wang T, Wang D, Yu H, Feng B, Zhou F, Zhang H, Zhou L, Jiao S, Li Y. A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors. Nat Commun. 2018;9:1532.

207. Stephan SB, Taber AM, Jileaeva I, Pegues EP, Sentman CL, Stephen MT. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol. 2015;33:97–101.

208. Oh JY, Kim HS, Palanikumar L, Go EM, Jana B, Park SA, Kim HY, Kim K, Seo JK, Kwak SK, Kim C, Kang S, Ryu JH. Coating nanoparticles with protein corona shield for targeted drug delivery. Nat Commun. 2018;9:4548.

209. Paliwal R, Babu RJ, Palakurthi S. Nanomedicine scale-up technologies: feasibilities and challenges. AAPS PharmSciTech. 2014;15:1527–34.

210. Jeanbart L, Kourtis IC, van der Vlies AJ, Swartz MA, Hubbell JA. 6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice. Cancer Immunol Immunother. 2015;64:1033–46.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.